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I 
 
Abstract 
 
Among people living with HIV/AIDS, tuberculosis caused by Mycobacterium tuberculosis 
(MTB) is the main cause of mortality with 430 000 deaths in 2011. Multidrug-resistant 
tuberculosis is on the rise, and no effective vaccine is available. 
 
HIV causes a depletion of CD4+ T helper cells, a cell subset that is of central importance in 
controlling mycobacterial infections. Although initiation of highly active antiretroviral 
therapy (HAART) in HIV patients results in increased CD4+ T cell counts, HIV patients still 
show, after treatment, increased susceptibility to mycobacterial infections. For unknown 
reasons, anti-mycobacterial T cell functions seem to be impaired in HIV patients despite onset 
of therapy. We hypothesize that in HIV patients the (poly)functionality of anti-mycobacterial 
CD4+ T cell responses as well as the memory T cell composition might be altered compared 
to healthy control subjects. 
 
In this study we therefore established and applied methods to investigate anti-mycobacterial 
CD4+ T cell effector functions and memory T cell subsets from peripheral blood 
mononuclear cells (PBMCs) of HIV infected individuals and healthy controls. Although 
freshly isolated PBMC were of superior quality, cells were found to retain their cytokine-
producing abilities if stored in liquid nitrogen but not at -80 °C. Isolated PBMCs were 
stimulated with antigens from Mycobacterium tuberculosis as well as Mycobacterium avium 
overnight. The next day the cells were analyzed by flow cytometry using a protocol with up to 
11 colours per sample to simultaneously examine CD4+ T cell effector functions and memory 
T cell phenotype. Effector cytokine production was also analyzed by ELISA and real-time 
PCR. 
 
We first examined the polyfunctionality of CD4+ T cells, which is the ability of T cells to 
respond to antigen-stimulation with simultaneous production of several T cell effector 
cytokines. Production of TNF, IL-2 and IFN-γ from CD4+ T cells was thus analyzed by flow 
cytometry.  
 
 II 
 
Different memory T cell subsets in the total as well as the mycobacteria-specific (cytokine-
producing) T cell population were next identified by flow cytometric staining with the 
markers CD27, CD28, CD45RO, CD57, HLA-DR, PD-1 and CCR7.  
 
With the chosen study protocol we analyzed so far samples of five healthy controls and seven 
HIV patients. Our preliminary findings show that a low number of CD4+ T cells produce 
mycobacteria-specific effector cytokines in response to M.tuberculosis and M.avium antigens 
both in healthy individuals and HIV patients. The degree of polyfunctionality was lower in 
HIV patients; cells simultaneously producing all three cytokines of interest was almost absent 
from this group. 
 
For memory T cell phenotyping there were no obvious differences for most markers when 
considering the total CD4+ T cell population, except a higher proportion of HLA-DR and PD-
1 in HIV patients than in healthy donors. When the simultaneous expression of CD27 and 
CCR7 was analyzed, findings point to that the mycobacteria-specific CD4+ T cells of healthy 
individuals are late differentiated, at a stage where expression of both CD27 and CCR7 are 
lost. Mycobacteria-specific CD4+ T cells of HIV patients seem to be of an earlier 
differentiated memory phenotype, as cells expressing both CD27 and CCR7 are predominant. 
 
In summary, we have established a study design to analyze mycobacteria-specific CD4+ T 
cells and memory T cells in blood samples from healthy individuals and HIV patients. A 
limited number of HIV patients and healthy control samples were analyzed and yielded some 
promising preliminary results. In the future, the protocol from this project will be used to 
analyze polyfunctional T cell responses against M.avium and M.tuberculosis as well as 
memory T cell composition in a larger cohort of HIV patients visiting the outdoor clinic at St. 
Olavs Hospital. 
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1. Introduction 
After HIV, no single infectious agent takes as many lives per year as Mycobacterium 
tuberculosis does (1). A total number of 8.7 million people were estimated to fall ill from 
tuberculosis in 2011, and 1.4 million estimated to die from it (1). Multidrug-resistant strains 
are on the rise, and no effective vaccine is available. Treatment is prolonged and expensive, 
and not easily available to all those who need it. 
 
Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis. About one third 
of the world's human population is infected with this bacterium, but in 90 % of the infected 
individuals, the bacteria persists in a dormant stage where it does not cause disease (2). If left 
untreated, the disease is potentially lethal. Risk of active disease is far greater in those with 
compromised immunity than in healthy individuals, and this is the reason why tuberculosis is 
a huge problem in patients co-infected with HIV/AIDS. In fact, tuberculosis is the main cause 
of death among HIV/AIDS patients (3). 
 
HIV (Human immunodeficiency virus) is a condition leading to immunosuppression as T cell 
numbers are lowered to a minimum level. This leads to increased risk of opportunistic 
infections, as T cells are of great importance to the immune system's ability to avoid 
challenges harmful to the human body. Tuberculosis is one of the opportunistic infections that 
can be acquired by HIV patients while T cell count is still relatively high, early in disease 
progression, and all people newly diagnosed with HIV should be tested for tuberculosis as 
soon as possible (3). With decreasing CD4 T cell count, the risk of active tuberculosis in HIV 
patients increases (4). HIV patients with latent tuberculosis are also at much higher risk for 
progressing to active tuberculosis disease than HIV negative individuals (3). 
 
This part will focus on the background for the study, the immune system as a general, and 
mycobacterial infections in detail. Both innate and adaptive immune response against 
mycobacteria will be covered, but T cells will be in focus, as they represent the major weapon 
against tuberculosis and are depleted in HIV patients. 
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1.1 The immune system 
The human immune system consists of two separate, yet intertwined, components; the innate 
immune system and the adaptive (acquired) immune system. 
 
The innate immune system is fully developed already from birth, and represents the first line 
of defense as pathogens try to enter the human body. It is characterized by rapid response, 
lack of memory and germline receptors only, and plays a major part in fighting pathogens. 
The innate immune system even eradicates a large number of infections before they are even 
allowed to enter the body (5). 
 
The innate immunity comprises both cellular and non-cellular components, among the latter 
are physical barriers like the gut flora, the mucus of the respiratory and gastrointestinal tract, 
hair/cilila, and antimicrobial components of tears and saliva (5). In addition, the complement 
system is said to be part of the innate immunity, although it can also be looked at as a link 
between the innate and adaptive immune system (reviewed in (6)). The complement system 
consists of many different small proteins circulating in the blood as precursor proteins, and 
they are activated by upon infection. The activation may follow one out of three different 
pathways, but they all lead to the same thing, namely pathogen lysis by the membrane attack 
complex (MAC). Small cleavage products from the complement activation may also opsonize 
pathogens for phagocytosis or recruit other immune cells by chemotaxis (reviewed in (7)). 
 
The most important cells of the innate immunity are the monocytes/macrophages and the 
granulocytes, and their major task in pathogen eradication is phagocytosis. Phagocytosis 
refers to the engulfment of solid particles by 'eater' cells, and more specifically describes how 
especially macrophages, but also neutrophils, destroy microbes by recognizing their presence 
and then destroying them before they can exhibit microbial activity to damage the host (8). 
Macrophages are extremely important for immune response towards mycobacterial infections, 
a topic that will be covered later on in this section (1.3). 
 
Cells of the innate immunity have no memory, and are dependent on recognizing pathogens 
and distinguishing self from harmful non-self. This is achieved through germline-encoded 
surface receptors on immune cells named pattern-recognition receptors (PRRs) that recognize 
Introduction 
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microbe-specific patterns named pathogen-associated molecular patterns (PAMPs). PAMPs 
are components of microorganisms that are essential for their survival, and therefore must be 
preserved during evolution (9). This, and the fact that these patterns are absent on human 
cells, ensures attack of pathogens only. Important PRRs for mycobacterial infections are the 
so-called Toll-like receptors (TLRs), discussed later in the text. 
 
In response to infection, various antimicrobial peptides and proteins are also secreted. 
Antimicrobial peptides are effectors of the innate immune system and offer a rapid response 
to invading pathogens (reviewed in (10)). Examples of antimicrobial peptides are the so-
called acute phase proteins like C-reactive protein (CRP) and complement factors that have 
opsonizing roles (reviewed in (11)), and lipocalin-2 (Lcn2), produced in response to bacterial 
stimuli to reduce bacterial growth by sequestering iron from bacteria (12). These effectors are 
secreted in response to TLR activation and cytokine secretion (11)(12). 
 
When infection cannot be cleared by the innate immune system, the adaptive immune system 
needs to be activated. The adaptive immune system develops from birth and needs to learn 
how to eradicate infections by encountering pathogens throughout life. It has four 
characteristic attributes; it is specific, diverse, has memory and shows self-nonself 
recognition. Its response is slower than that of the innate immunity, but it shows a rapid 
response for secondary, repeated infections with the same infectious agent (reviewed in (13)). 
 
Adaptive immune response depends on lymphocytes and antigen-presenting cells (APCs). 
Lymphocytes are a subgroup of leukocytes and comprise the B cells and the T cells. B cells 
produce antibodies (immunoglobulins) upon activation and these antibodies bind to antigens 
(antibody generator, Ag) on pathogens to facilitate their clearance from the body. Antibodies 
produced by B cells belong to the humoral branch of the immune system, a system that is 
highly effective to clear infections consisting of free antigens circulating in the body 
(reviewed in (7)). As they are believed to have limited impact on mycobacterial infections, B 
cells and immunoglobulins will not be discussed a lot in this text. It should however be noted 
that recent findings point to a possible role for B cells in immunity against tuberculosis 
(reviewed in (14) and (15)), as this population possibly may influence cytokine production. 
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T cell-mediated adaptive immunity, however, is considered central in defense against 
mycobacterial infections. T cells arise in the bone marrow and mature in the thymus before 
they migrate to lymphatic tissues where they become activated. T cells bear a unique antigen-
binding T cell receptor (TCR) associated with a CD3 co-receptor, and this TCR determines to 
what specific antigen the T cell clone can mount a response. To become activated, T cells 
depend on encountering antigen-derived peptides associated with Major histocompatibility 
complex (MHC) molecules on the cell surface of so-called antigen-presenting cells (16). 
Examples of professional APCs are dendritic cells (DCs) and macrophages. The major T cell 
subsets are CD4+ and CD8+ T cells. CD4 T cells mainly recognize exogenously derived 
antigens presented in the context of MHC class II, whereas CD8 T cells mainly recognize 
endogenously derived antigens presented in the context of MHC class I. Upon activation by 
antigen contact, the T cell starts proliferating, producing an entire army of monoclonal T cells, 
thus with identical antigen specificity as the progenitor cell itself (17). In addition to the two 
main T cell subsets mentioned above, several unconventional T cell subsets exist, such as 
Natural killer T (NKT) cells (reviewed in (18)), γδ T cells (reviewed in (19)) and CD1-
restricted T cells (reviewed in (20)). 
 
Upon activation, differentiation into effector cell subsets also takes place. CD8 cells develop 
into cytotoxic T lymphocytes (CTLs) which possess direct cytotoxic activity, whereas CD4 T 
cells can develop into a variety of effector cells (see section 1.4.2). Both CD4 and CD8 T 
cells produce effector molecules called cytokines (17). Cytokines direct the immune response 
by exerting a variety of effects on all other cells of the immune system. CD4 T cells and their 
effector functions will be thoroughly covered in the rest of the text, as they represent one of 
the key components of this work. 
1.2 Mycobacterial infections 
The etiological agent causing tuberculosis was discovered by Robert Koch in 1882 (described 
in (21)). The disease is caused by Mycobacterium tuberculosis (MTB), an acid-fast and rod-
shaped bacterium. The bacteria are slow-growing and surrounded by a thick and wax-rich cell 
wall (22). After the whole genome of the bacteria was published in 1998 (23) it was found 
that more than 250 of the bacteria's genes are involved in fatty-acid metabolism, producing 
substances of the cell wall. The most important components of the cell wall are different 
forms of mycolic acids. The presence of this characteristic cell wall is important for the 
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virulence of the bacteria. It prevents the attack of the bacteria by medical drugs, and also 
inhibits their dehydration. In addition, it slows the rate of nutrients entering the bacteria, and 
although this may seem as a drawback, it may actually also explain why the bacteria is such a 
strong pathogen and causes chronic infection (24)(25), as it results in prolonged exposure to a 
large diversity of antigens (reviewed in (26)). 
 
The disease is very contagious and the bacteria are primarily transmitted through the 
respiratory route leading to pulmonary disease of the lungs (27), see figure 1.1. Droplets 
containing bacilli are expelled by infected individuals and inhaled by anyone in close 
proximity. The bacilli end up in the lung where they are engulfed by alveolar macrophages. 
Macrophages residing in this part of the lungs are especially active as they guard one of the 
main entrances to the body. As a response to the detection of invaders, cytokines are produced 
from macrophages and various inflammatory cells are recruited to the lungs. Macrophages are 
often unable to fully eradicate the pathogen. Instead, the bacilli are able to survive and 
replicate inside the host macrophage until macrophages burst and release large numbers of 
bacilli. As specific T cells are recruited a few weeks after infection, they induce the 
infiltration of macrophages and the formation of so-called granulomatous lesions, or 
tubercles. These lesions contain Th1 cells and infected macrophages and have a necrotic 
middle due to the release of lytic enzymes from the activated macrophages and the subsequent 
destruction of nearby cells. Due to a non-favorable environment and the presence of activated 
macrophages in the surroundings, the bacilli are not able to replicate within the granulomas, 
instead they slow down their growth and enter a latent stage where disease is not developed, 
this stage is called latent TB infection (LTBI) (28)(29). A dynamic balance develops between 
bacterial persistence and host defense, and this balance may be long-lasting, and even 
lifelong. Up to one third of the world's population have been infected with this infectious 
agent, but for 90 % of these individuals dormancy and latency maintains and they live their 
life without any obvious signs of disease. If they ever become immunodeficient, by for 
example an HIV infection, chance of reactivation is increased and they may experience active 
tuberculosis. 
Introduction 
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Figure 1.1: Pathogenesis of tuberculosis. Bacilli are inhaled through the respiratory tract and reach the 
lungs. They first encounter alveolar macrophages and become phagocytosed, leading to the subsequent 
production of proinflammatory cytokines. This attracts other immune cells in the formation of so-called 
granulomas where bacilli slow growth and enter dormancy. In granulomas, bacteria persist in a state 
where they do not cause active disease. However, if individuals become immunosuppressed, granulomas 
may burst and bacilli are spread to cause active disease. Figure from (30).  
 
Mycobacterium avium is a close relative to Mycobacterium tuberculosis, also capable of 
causing human disease. M.avium is often grouped with M.intracellulare in formation of the 
Mycobacterium avium complex (MAC). M.avium is able to cause pulmonary disease in 
immunocompromised individuals, children and elderly people, and the disease is often hard to 
get rid of. MAC disease in patients with AIDS is a serious complication of HIV. However, the 
introduction of highly active antiretroviral therapy (HAART) for HIV patients has reduced the 
number of people at risk for the disease (described in (31)). Due to the fact that M.avium 
shares many properties with its better known relative, and its less stringent biosafety level 
needs, the bacteria is often used as a model organism for Mycobacterium tuberculosis (32). 
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1.3 Innate immunity and mycobacterial infection 
As Mycobacterium tuberculosis first enters the body, the bacteria encounter alveolar 
macrophages that are part of the innate immune system. The containment of the bacteria is 
dependent on cooperation between the innate and adaptive immunity where macrophages, T 
cells and several cytokines play a central part. In the initial phase of the mycobacterial 
infection, antimicrobial proteins of the innate immune system, such as lipocalin-2 (Lcn2), 
may help limit extracellular growth of mycobacteria (33). 
 
Macrophages are important effector cells for fighting intracellular pathogens, among them 
M.tuberculosis. The bacteria, in turn, have converted this attribute into exploting their key 
killer as their preferred habitat. The central role for eradication of pathogens by macrophages 
is dependent on their recognition of harmful non-self, usually by PRRs recognizing PAMPs, 
as explained earlier in the text. It is generally accepted that M.tuberculosis is engulfed by 
macrophages by conventional phagocytosis (34). The two processes of recognition and 
phagocytosis are facilitated by two different classes of macrophage surface proteins. For 
recognition of bacteria, Toll-like receptors (TLRs), NOD-like receptors (NLRs) and C type 
lectins (e.g DC-SIGN) are found, whereas complement receptors, mannose receptors and 
scavenger receptors are important for the uptake of bacteria (figure 1.2). 
 
1.3.1 Immune recognition and macrophage uptake of Mycobacterium 
tuberculosis 
Toll-like receptors (TLRs) were originally identified (and named Toll, meaning «great» in 
German) in Drosophila and found to control the antifungal response in flies (35), but similar 
molecules were later also discovered in the human species (36). To date, there are 12 known 
variants in humans (TLR1-TLR12) (reviewed in (37)), and their task is to recognize PAMPs. 
TLRs are membrane-spanning glycoproteins, some of them situated on the cell surface, and 
others in intracellular compartments. All TLRs specialize in recognition of conserved 
microbial patterns to sense pathogens and thereby inducing an immune response.  
 
Not all known TLRs are believed to be involved in MTB recognition. To date, TLR2, TLR4, 
and TLR9 seem to be most important (reviewed in (24)). Upon recognition of MTB PAMPs, 
different signaling pathways are triggered, leading to the activation of an appropriate immune 
Introduction 
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response. Intracellular adaptor protein MyD88 seems to play an important part as it associates 
with β receptor-associated kinases (IRAK) in activation and nuclear translocation of nuclear 
transcription factor NF-κB. The end result of this is the production of proinflammatory 
cytokines like IL-1β (interleukin 1β), TNF (tumor necrosis factor), IL-6, IL-18 and several 
others (reviewed in (24)). 
 
 
 
 
 
Figure 1.2: Immune recognition and uptake of M.tuberculosis. Different Toll-like receptors (TLRs) 
recognize pathogen-associated molecular patterns (PAMPs) of the mycobacterial cell, including 
lipoproteins (TLR2), lipoarabinomannan (LAM) (TLR4) and DNA (TLR9). This activates an intracellular 
signaling cascade in the host cell. Adaptor protein MyD88 is often involved, as is IL-1 receptor-associated 
kinases (IRAK), leading to the subsequent translocation of transcription factor NF-κB and the production 
of proinflammatory cytokines like IL-1β. Uptake of bacilli for phagocytosis is facilitated by different 
receptors on the host cell, including complement receptors, mannose receptors and scavenger receptors. 
Some of the receptors require bacilli are opsonized with complement split products, but they can also be 
taken up without these. After uptake, bacilli rest in phagosomes, where they inhibit immune activation by 
inhibition phagosome-lysosome fusion. Figure from (28). 
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In mycobacterial infections, TLRs activate the immune system by recognizing a key 
component of the mycobacterial cell wall; the glycolipid lipoarabinomannan (LAM), probably 
much like TLR4 is known to sense LPS of Gram negative bacteria. In addition, TLR4 may be 
activated by heat-shock proteins (hsp) produced by the bacilli. TLR2 are also able to 
recognize acylated mycobacterial lipoproteins, whereas TLR9 is believed to recognize 
unmethylated CpG motifs in mycobacterial DNA (reviewed in (24)). 
 
In addition to TLRs, other macrophage molecules also help in mounting an immune response. 
NOD-like receptors (NLRs) are involved in the inflammasome formation and the subsequent 
production of IL-1β. C-type lectins like Dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) and dectin-1 may also be involved as PRRs 
when macrophages encounter M.tuberculosis (reviewed in (24)). 
 
Macrophages will try to eliminate MTB in several ways; among them are the production of 
reactive oxygen and nitrogen species (ROS and RNS, respectively), acidification of the 
phagosome and phagosome-lysosome fusion (reviewed in (28)). First, however, the bacilli 
need to be engulfed by the macrophage, a process that is mediated not through the TLRs 
themselves, but by other mycobacteria-binding receptors on the macrophage surface. 
 
Complement receptors (CR) present on the surface of immune cells are able to promote 
engulfment of particles opsonized with complement components like C3 (34). It was shown 
that CR1, CR3 and CR4 mediate uptake and phagocytosis of Mycobacterium tuberculosis, 
and it is possible even for non-opsonized bacilli to bind to some of the complement receptors. 
Still, the favorable mechanism for uptake of non-opsonized bacteria is through the mannose 
receptor recognizing terminal mannose residues (38), one example of a ligand being LAM, 
discussed earlier as a TLR ligand as well. There are also other molecules facilitating the 
uptake of M.tuberculosis (reviewed in (28)), among them scavenger receptors. It has even 
been proposed that the mechanism by which the bacilli are taken up in to the macrophages, 
decides their fate (reviewed in (39)). 
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1.3.2 Life inside the macrophage 
As bacteria are taken up by macrophages and macrophages are activated, bacterial killing by 
phagocytosis is performed by the macrophages. The material taken up is enclosed within a 
membrane-bound phagosome, and the ingested material is degraded through the action of a 
series of hydrolytic enzymes (reviewed in (40)). 
 
Mycobacterium tuberculosis is one of the most successful pathogens when it comes to 
escaping from the immune system, and is therefore able to survive within macrophages for a 
long period of time. As the phagosome presents a harsh environment for the bacilli, 
M.tuberculosis arrests phagosome maturation and inhibits phagosome-lysomsome fusion. In 
this way, the bacilli prevent the digestive activity of acidic hydrolases that would otherwise 
threaten their existence (41). 
 
Although the bacilli enter a state of slow growth and dormancy within the macrophages, they 
are still dependent on a steady supply of iron for their survival. Ironically, the iron is also 
essential for some host-defense mechanisms, and as the bacilli successfully competes for iron 
with the host, it promotes its own survival and suppress host-defense. The arrest of 
phagosome maturation give the bacilli free access to iron as iron is taken up bound to 
transferrin through transferrin receptors and then trafficked to early endosomal compartmens 
(reviewed in (39) and (42)). Mycobacteria have also developed a type of iron-binding 
molecules, so-called siderophores, that transfer iron molecules from host proteins to the 
mycobacterial cell wall (43). The host's answer to the bacterial siderophores is lipocalin-2 
(Lcn2), an iron sequestering innate immune protein that is able to bind iron with higher 
affinity than most bacterial siderophores and thus can starve bacteria for iron (12). Lcn2 is 
readily produced and stored for secretion in neutrophils, and production can be induced in 
other cell types such as hepatocytes in infected liver tissue (Haug et al. 2013, submitted). 
However, if infected macrophages take up Lcn2 from the surroundings, it is directly degraded 
by the endosomal pathway, whereas iron bound to transferrin ends up in the recycling 
compartment where the mycobacteria resides (33). Thus, Lcn2 seems to have no effect on 
intracellular bacteria like mycobacteria. 
 
If IFN-γ is present in the environment, macrophages become fully activated (44). This, in 
turn, increases the production of reactive oxygen and nitrogen species, it promotes 
acidification of phagosomes and the fusion of phagosomes to lysosomes. IFN-γ may be 
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produced in response to IL-12 and IL-18, from Natural killer (NK) cells early during 
infection, or T cells after adaptive immunity has been activated (45). Even activated 
macrophages are unable to fully eradicate M.tuberculosis infection (described in (22)), but 
this activation and antimicrobial activity is essential for the containment of bacteria and the 
prevention of active disease. 
 
The bacilli are able to persist in the host in a dormant stage and stay this way until the host 
defenses are down, like they are in for example HIV infection (46). They are then able to 
reactivate and cause active tuberculosis.  
1.4 Adaptive immunity and mycobacterial infection 
 
Mycobacterium tuberculosis is an intracellular bacterium, and host protection therefore 
mainly relies on cell-mediated immunity, and primarily T cells.  
 
The bacteria are taken up by macrophages by phagocytosis (as described in 1.3.1), but may 
also enter dendritic cells (DCs) in the lungs and reside within them. Interactions between 
bacilli and DC are poorly understood, but seem to have an important impact on the initiation 
of a protective immune response (47)(48)(49), as DCs have an important role as APCs. 
 
Normally, exogenously derived antigens such as bacterial antigens are taken up and trafficked 
to a phagosome. Presentation with MHC class II is the natural choice, this attracts CD4 T 
cells and leads to the subsequent activation of CD4+ T cells and differentiation into various 
effector subsets. Phagolysosomal arrest by M.tuberculosis affect the macrophage's ability to 
process and present mycobacterial antigens to CD4+ T cells in a MHC class II context and 
thereby infers with the whole adaptive immune response, as CD4+ T cells are dependent on 
antigen-presenting cells such as macrophages and DCs to become activated. For exogenously 
derived antigens to be presented on APC surfaces, the internalized antigens need to be 
processed and associated with MHC class II molecules. This involves fusion of intracellular 
vesicles, a process inhibited by mycobacteria. Due to this, it is conceivable that the Ag 
presentation is decreased in mycobacterial infections (50). It was also described that a 19 kDa 
lipoprotein antigen of M.tuberculosis downregulate MHC class II due to intraphagosomal 
TLR2 stimulation (51). 
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Despite this, mycobacterial antigens are presented in both a MHC class I and a MHC class II 
context (reviewed in (22)). Presentation to CD8+ T cells is made possible as infected APCs 
release extracellular vesicles as they undergo apoptosis. The vesicles contain mycobacterial 
antigens and are taken up by bystander APCs, leading to the subsequent presentation with 
MHC class I and the activation of CD8+ T cells (52). 
 
Activation of adaptive immune cells is accomplished despite the bacteria's evasion strategies 
of phagolysosome maturation arrest and MHC II downregulation in innate immune cells. The 
activation of CD4+ Th1 cells are assumed most important in defense against mycobacteria, as 
will be highlightened in the following sections. 
1.4.1 T cells 
T cells are a key component of the human immune protection. Their importance is 
indisputable; they activate B cells and macrophages, they recruit granulocytes to site of 
infection, they orchestrate the entire immune system through their cytokine production, and 
some even exhibit direct cytotoxic activity. One striking example of their importance can be 
seen among HIV patients that show a depletion of their CD4 T cell population. These patients 
are extremely prone to opportunistic infections, and the risk of infection is inversely 
proportional to the CD4 T cell count. 
 
T cells arise from the hematopoietic stem cells in the bone marrow and migrate to the thymus 
where they mature as so-called thymocytes. In the thymus they go through a series of 
developmental steps including the rearrangement of their T cell receptor to achieve a broad 
range of specificities towards different antigens. The thymocytes also experience two 
selection steps to ensure they are able to mount a response towards their specific non-self-
antigen, but not towards self-antigens. When the naïve T cells (i.e. cells that have not yet 
encountered antigen) leave the thymus, the main subsets express one out of two characteristic 
surface molecules; CD4 or CD8, the choice directing their future activities (reviewed in (53)). 
T cells continuously recirculate through the blood and lymph to lymphoid organs like the 
spleen and lymph nodes. T cells stay in the blood for only 30 minutes, but spend 12 hours in 
the lymph nodes before circulating further (54). 
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The next step for naïve T cells is to meet the one antigen to which the T cell can mount a 
response. The antigen encountering happens in secondary lymphoid organs like the lymph 
nodes, where professional APCs present processed antigens associated with MHC on their 
surface. T cell activation requires two signals; peptide from processed antigen (matching its T 
cell specificity) presented in the context of MHC class I (CD8 T cells) or MHC class II (CD4 
T cells) on antigen-presenting cell (APC) and a costimulatory signal from the interaction 
between CD28 (on the T cell) and B7 (on the APC). Upon activation, a signaling cascade is 
initiated in the T cells, resulting in the translocation of transcription factors and the sub-
sequent changes in gene expression and the production of cytokines and other characteristic 
markers (reviewed in (55)). For four to five days the cell divides two to three times every day, 
creating a monoclonal population of progeny cells. These cells differentiate into different 
subpopulations; effector T cells and memory T cells. The effector T cells are characterized by 
a profound cytokine production and they express markers affecting their recirculation pattern. 
Effector cells are derived from naïve T cells, but also from memory T cells after antigenic 
activation. Memory T cells are antigen-experienced, long-lived and responsible for the 
secondary response (see 1.4.4). 
 
Naïve T cells migrate preferentially to the tissues where they will encounter antigen, a process 
named homing. This increases the chance of a naïve T cell meeting its antigenic counterpart. 
It is the presence of adhesion molecules like selectins (e.g CD62L) on the T cell surface that 
controls the homing of cells (reviewed in (56)). Antigen-experienced T cells display different 
migration patterns, and this is reflected by different sets of surface markers. Upon activation, 
effector T cells downregulate the expression of CD62L and CCR7, two of the most important 
molecules for homing to secondary lymphoid organs (reviewed in (57)). At the same time, 
they upregulate homing molecules that target them to infected non-lymphoid tissues. They 
recognize inflamed vascular endothelium and chemokines, and exert their effector functions 
in the same non-lymphoid tissue region as the one where they were first activated (reviewed 
in (57)). 
 
Memory T cells are antigen-experienced and have less stringent requirements for activation 
than do naïve T cells. In 1999, a pivotal study classified them as either central memory cells, 
TCM, or effector memory cells, TEM (58). Central memory cells express CCR7 and thus home 
to secondary lymphoid organs. They secrete IL-2 and can give rise to effector T cells that 
Introduction 
___________________________________________________________________________ 
14 
 
migrate to site of infection (59). Effector memory cells lack CCR7 and thus the ability to 
home to secondary lymphoid organs. Instead, they home to non-lymphoid tissue and can 
rapidly secrete a variety of cytokines. There is still some controversies and much uncertainty 
about the memory T cell population (reviewed in (60)), and everything about it is still not 
uncovered. There is also another part covering memory subsets later in the text (1.4.4). 
 
Mycobacteria reside in vesicles within macrophages or DCs, and are therefore most likely to 
be presented with MHC class II, and activate CD4+ T cells. For this to happen, T cells depend 
on the activity of professional antigen-presenting cells (APCs), like macrophages or DCs. It is 
believed that DCs play an important role in activating the adaptive immune system in 
mycobacterial infections. DCs encounter mycobacterial antigens in the lungs and then migrate 
to draining lymph nodes where they present antigen to naïve T cells (reviewed in (61)). Naïve 
CD4 or CD8 T cells, activated by antigenic peptides presented in the context of MHC class II 
or MHC class I, respectively, undergo proliferation and traffic back to the lung (reviewed in 
(61)). In the lung, T cells produce a wide variety of cytokines that influence the outcome of 
mycobacterial infection by affecting the macrophage bactericidal capacity (IFN-γ, TNF), 
granuloma formation and maintenance (TNF, IL-1), activation of Th1-responses (IL-12), 
recruitment of effector cells (IL-8), increased (IL-6) and decreased (IL-10) effector responses 
in target T cells and macrophages (reviewed in (62), (63) and (64)). 
 
As mycobacterial antigens are most likely to be presented in association of MHC class II, 
CD4 T cells are despite phagolysosomal arrest activated in mycobacterial infections. As IFN-
γ producing Th1 cells are considered central in antimycobacterial immunity, CD4+ T effector 
cell subsets will therefore be more closely described in the next paragraph (1.4.2). However, 
CD8 T cells can also be activated by the mechanisms earlier mentioned and also have a role in 
fighting M.tuberculosis infection (65)(66), as well as unconventional γδ T cells (reviewed in 
(39)). CD8 T cells play an important part in clearing virus-infected cells, and they are also 
capable of producing a set of cytokines, including IFN-γ, TNF and IL-2 (reviewed in (67)). 
1.4.2 CD4 T cell subsets 
The CD4 T cell population can be further divided into several subpopulations and the 
development of the different subsets is directed by the cytokine milieu in the environment 
during activation. The differentiation of one lineage often suppresses the other sub-
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populations, for example IFN-γ produced by Th1 cells inhibits development of Th2 cells (68). 
A summary of the differentiation of the CD4 T cell population can be found in figure 1.3.  
 
Figure 1.3: Differentiation of naïve T cells. Based on the cytokine environment, naïve T cells can 
differentiate into four major subsets; Th1, Th2, Th17 and iTreg. IFN-γ and IL-12 induces differentiation 
to the Th1 lineage, as well as transcription factors T-bet and Stat4. The Th1 cells produce cytokines that 
are important in infections with intracellular pathogens and autoimmunity. Th2 cells are induced by 
cytokines IL-2 and IL-4 and transcription factors GATA-3 and Stat5. Th2 cells are involved in the 
eradication of extracellular parasites, as well as in allergy and asthma. Cytokines TGF-b, IL-6, IL-21 and 
IL-23, as well as transcription factors RORγt and Stat3 induce differentiation to Th17 cells that are 
involved in immunity against extracellular bacteria and fungi. Last, in the presence of TGF-b and IL-2 
and transcription factors Foxp3 and Stat5, regulatory Tregs are induced. These cells produce anti-
inflammatory cytokines and are involved in the negative regulation of other T cell subsets. Figure from 
(69). 
 
The first two subsets discovered were the Th1 and the Th2 subsets in 1986 (70). The two 
groups were distinguished based on their cytokine production; Th1 cells produced IFN-γ as 
their signature cytokine, whereas Th2 produced IL-4. It was later concluded that the cytokine 
profile of the subsets defined their role in the immune system, as Th1 cells were found to fight 
intracellular pathogens, as opposed to Th2, playing an important role in immunity against 
extracellular pathogens and in allergy and asthma (reviewed in (67) and (71). 
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Th17 is a newly identified class of effector T cells (72)(73) (74) producing IL-17 among 
others, this subset being involved in eradication of extracellular bacteria and fungi. 
 
The fourth major CD4 T cell subset are the (induced) regulatory T cells, iTreg (75). These 
cells display immune-suppressing activity, and produce anti-inflammatory cytokines like IL-
10 and TGF-β (76). 
 
Th1 are perhaps the most important T cell subset for mycobacterial infections, due to their 
role as potent IFN-γ producers. As already mentioned, IFN-γ are powerful macrophage 
activators, and this activation is crucial for mycobacterial containment. People with defects in 
interferon γ or its receptor show an increase in susceptibility towards mycobacteria (reviewed 
in (77)), proving how IFN-γ is required for host defense and survival. More recent indications 
show that IFN-γ alone is not enough for host protective immunity against M.tuberculosis, and 
that other cytokines need also be considered. Polyfunctional T cells, cells simultaneously 
producing more than one cytokine, has received a lot of interest lately. The important role for 
IFN-γ and other cytokines in mycobacterial infections is explained in more detail in 1.4.3.  
1.4.3 Cytokines 
Cytokines are secreted low-weight protein signaling molecules acting in an autocrine or 
paracrine manner in the body. They regulate the intensity and duration of the immune 
response by directing the activity of all other immune cells. Cytokines may be either 
proinflammatory, promoting systemic inflammation, or anti-inflammatory, inhibiting 
inflammation (reviewed in (78)). Each cytokine has a matching cytokine receptor on the 
surface of the cell it is supposed to regulate, and this receptor and the subsequent intracellular 
signaling cascade makes it possible for the cytokine to induce a variety of biological effects in 
nearby cells, like upregulation or downregulation of genes. Four recognized and important 
cytokine attributes are; pleiotropy, redundancy, synergy and antagonism, and they often form 
complex cytokine networks. Due to their widespread activity, cytokines need to be tightly 
regulated, and any disturbance to this regulation may seriously interfere with the immune 
balance (79). 
 
This part will focus on three main cytokines that are associated with defense against 
mycobacteria and can be produced from CD4+ Th1 cells; IFN-γ, TNF and IL-2. Th1 cell 
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subsets can produce one, two or all three cytokines simultaneously (polyfunctionality of T 
cells). Additional cytokines IL-1β and IFN-β will also be discussed in brief, as they were 
chosen as targets during PCR. 
 
IFN-γ is important in the control of MTB infection (80), as it is a key activator of 
macrophages (figure 1.4). IFN-γ is mainly produced by Th1 cells after activation, but can also 
be produced by natural killer (NK) cells, APCs and CD8 T cells. IFN-γ importance was 
confirmed in 1993 as it was found that mice with IFN-γ knock out (GKO) could not control 
even small doses of Mycobacterium tuberculosis (81). Instead, the mice experienced 
widespread tissue destruction and necrosis. 
 
Interferon γ is the only type II interferon, and it is essential for intracellular pathogens, virus 
control and tumor immunity. IFN-γ secretion by NK cells and APCs are believed to be of 
great importance early in infection, but T cells become the major source in adaptive 
immunity. Production of IFN-γ is controlled by the cytokine environment. As macrophages 
sense the presence of for example M.tuberculosis through their PRRs, the production of 
proinflammatory cytokines are upregulated, among them IL-12 and IL-18. These cytokines 
induce the IFN-γ production in for example T cells. The IFN-γ then affect the macrophages 
again, making them active and increase the antimicrobial activity. Anti-inflammatory 
cytokines IL-4, Il-10 and TGF-β function as negative regulators of IFN-γ. IFN-γ primarily 
signals through the Jak-Stat pathway (82). 
 
In T cells, IFN-γ mRNA is detectable shortly after T cell stimulation, as it belongs to the 
group of «early» genes expressed in activated T cells. mRNA expression is detectable as soon 
as 30 minutes post antigen encounter (83). 
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Figure 1.4 Activation of macrophages by cytokine IFN-γ. Mycobacterial pathogen-associated molecular 
patterns (PAMPs) activate macrophage TLRs during early stages of mycobacterial infections. This 
activation leads to the production of proinflammatory cytokines such as IL-12 from the infected 
macrophage. Macrophages present processed mycobacterial antigens associated with MHC class II to 
CD4+ T cells. In addition to the presence of IL-12 in the surroundings, this leads to the production of IFN-
γ by activated CD4+ T cells. IFN-γ then stimulates and activates nearby macrophages that answer by 
upregulating their microbial activity. Figure from (84). 
 
However, IFN-γ is not the only Th1 specific cytokine important for mycobacterial infections, 
and other cytokines have proved their importance as well, among them TNF and IL-2 
(reviewed in (85)).  
 
TNF was in 1995 associated with survival and control of Mycobacterium tuberculosis 
infection in mice (86). In the absence of a receptor for TNF, mice succumbed on average 22 
days postinfection, while the control mice lived throughout the whole experiment. TNF is an 
inflammatory cytokine that induce a broad spectrum of biological effects, including apoptosis 
and translocation of NF-κB to increase production of cytokines and the expression of 
adhesion molecules. TNF can also contribute to the activation of macrophages, as reviewed 
by (87). TNF is ineffective alone, but synergizes with IFN-γ in induction of NO production 
and RNIs. The cytokine is also important in granuloma formation, perhaps due to its influence 
on chemokines and chemokine receptors (88). 
 
TNF is also believed to accumulate early in immune response. Its mRNA was reported to 
peak between two and four hours after LPS stimulation in lymphocytes (89), whereas others 
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(83) reported the TNF-β mRNA to be detectable 1-3 hours post stimulation. It has been shown 
by other members in the research group that during ELISA, TNF is the first detectable 
cytokine in supernatant from stimulated PBMCs, even before IFN-γ. However, TNF levels 
decrease rather rapidly and seem to be almost gone when IFN-γ peaks (unpublished 
observations). 
 
IL-2 is discussed as the third Th1 cytokine important in mycobacterial infections. The 
cytokine describes the status of the T cell population, as it is necessary for proliferation and 
differentiation of T cells to effector memory cells, and thus the generation of long-term 
protective immunity (90). Expression of IL-2 also upregulates the expression of IL-2 receptor 
(IL-2R = CD25) and synthesis of IFN-γ in human T cells (91). The simultaneous expression 
of IL-2R on T cells also makes it possible for the IL-2 produced to act as an autocrine 
signaling molecule on the population from which it arose. 
 
Polyfunctional Th1 cells, meaning Th1 cells that produce all three cytokines, have been 
proposed to be particularly potent in controlling MTB infection (92)(93). This finding was 
first recognized in the protozoa Leishmania major(94), but the effect is likely to apply to 
tuberculosis as well. Polyfunctional T cells (PFT) are often targets in immunoassays when 
considering mycobacterial infections (95)(96), as it has been shown to correlate with long-
term protective immunity against tuberculosis (97). Others, however, claim that this 
polyfunctionality alone fails to predict protective immunity (98). 
 
Proinflammatory IL-1β is first produced by alveolar macrophages upon encountering 
M.tuberculosis and the subsequent signaling through Toll-like receptors (TLRs) (99). IL-1β 
induce fever, the acute phase response and the stimulation of neutrophil production. As TLRs 
sense mycobacterial PAMPs, a signaling cascade is initiated resulting in the translocation of 
NF-κB and the subsequent production of pro-IL-1β. A so-called inflammasome is assembled 
as a response to intracellular danger-associated molecular patterns (DAMPs). Through the 
action of the protease caspase-1, the inflammasome converts pro-IL-1β to its active form, IL-
1β, that is later secreted. The role for IL-1β in host defense against M.tuberculosis was 
demonstrated as mice deficient in IL-1 receptor type I (IL-1RI) suffered fatal consequences 
upon infection with the bacteria (reviewed in (99)). 
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Fibroblasts are the main source of interferon beta (IFN-β), but they can also be produced by 
dendritic cells (DCs). IFN-β mediate a variety of immunoregulatory effects, including an 
increase in NK cytotoxic activity. IFN-β may also enhance IFN-γ production (reviewed in 
(100)). 
1.4.4 T cell memory status 
Memory T cells are derived from naïve T cells after they encounter antigen and from effector 
T cells after antigenic activation and differentiation. They are antigen-experienced and long-
lived and respond with a strengthened reactivity towards repeated infections with the same 
infectious agent, known as the secondary response. This small population remains for a long 
time after the primary response has declined, and circulate in the body looking to reencounter 
the same antigen once more. Memory T cells seem to have less stringent needs for activation 
than do naïve T cells. They may be activated by a broad range of cells, this in contrast to 
naïve cells that need to be activated by professional APCs. This is believed to be due to the 
heightened expression of surface markers like numerous adhesion molecules (101). 
 
Several surface markers help identify the differentiation status of the T cell population, but a 
lot is still unknown about the memory T cell population, their markers and their effector 
functions. Memory T cells express many of the same surface markers as effector T cells, and 
no set of markers clearly defines them as memory T cells. The memory population is very 
heterogeneous and surface markers expression gradually change over time during 
differentiation. This part will look into what is already known in this field, focusing on a set 
of memory markers believed to be important in this context, namely CD45RO, CD27, CD28, 
CD57, PD-1, HLA-DR and CCR7. Part of this thesis work includes the investigation of how 
expression of memory surface markers differs in HIV patients and healthy controls. 
 
Markers like CD45RO (or its counterpart, CD45RA), and CCR7 are typically used to describe 
memory differentiation, but CD27 and CD28 may be beneficial in further subdividing the 
major memory populations. It may also be that the phenotype resulting from expression of 
CD27 and CD28 overlap with the populations characterized based on CD45 and CCR7 
expression (102). It can generally be said that the expression of CD27, CD28, and CCR7 are 
lost as differentiation proceeds, whereas CD45RO expression is increased, before it seems to 
be lost again at terminal differentiation. CD57 and PD-1 are both useful when describing cells 
at the end of the differentiation pathway, at replicative senescence. 
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A short description of some memory markers follows. 
 
 CD45 (Cluster of differentiation 45) is perhaps the oldest known epitope on T cells 
reflecting their memory phenotype. Naïve T cells bear a variant called CD45RA on their 
surface, but as they encounter antigen, they differentiate to a CD45RO phenotype (103) 
(104). This is made possible from the alternative splicing of exon 4/5/6 (A/B/C). 
Activation leads to a programmed shift in splicing, resulting in the decrease of the high 
molecular weight isoform (CD45RA) and a subsequent increase in the low molecular 
weight isoform, the null form (CD45RO) (described in (105)). Terminal effector cells may 
lose the expression of CD45RO (106). 
 
 CD27 is a costimulatory signal and a member of the tumor necrosis factor receptor 
(TNFR) family. It is expressed on all naïve T cells and on most memory cells, but seem to 
be lost during memory differentiation (107)(108).  
 
 CD28 is perhaps the most important costimulatory molecule for T cell activation, and it is 
expressed on all mature thymocytes. Loss of CD28 expression has been coupled to T cell 
replicative senescence (109). It has been proposed that an increased proportion of CD28- 
cells in HIV patients explains their increased risk of aging-associated diseases (110). 
 
 CD57 is a surface marker that defines replicative senescence in CD4+ and CD8+ T cells 
(111). 
 
 PD-1 (Programmed cell death protein 1), also known as CD279, negatively regulates T 
cell responses, and is in HIV associated with T cell exhaustion and disease progression 
(112). In healthy individuals, the marker is preferentially expressed on effector memory 
cells (113). 
 
 HLA-DR is a MHC class II cell surface receptor that is part of the human leukocyte 
antigen (HLA) system. Its main task is to present antigenic peptides to other cells of the 
immune system. Expression on T cells is often increased in response to stimulation, and 
HLA-DR is therefore also recognized as an activation marker (114). It is proposed that 
this makes the T cells capable of presenting Ag to other cells (described in (115)). 
Introduction 
___________________________________________________________________________ 
22 
 
 
 CCR7 (C-C chemokine receptor 7), or CD197, is a chemokine receptor that has an 
important role in recirculating and homing of lymphocytes (116). CCR7 is expressed by 
all naïve T cells, and some memory cells. In fact, CCR7 is believed to divide the memory 
cell population in two distinct subpopulations (58). 
 
Naïve T cells express CD27, CD28, CD45RA and CCR7. 
 
Central memory T cells, TCM, express CCR7 (and CD62L
hi
) and are able to home to lymphoid 
organs. They lack the ability to immediately start producing cytokines (they do produce some 
IL-2), but they divide rapidly upon an antigen reencounter and can then even differentiate 
further to effector cells (58). Central memory T cells are described as CD45RO+CD28+ 
phenotype (85)(117), additionally CCR7 (and CD62L
hi
) might be used to describe them. 
Central memory T cells are a population that is directly derived from naïve T cells after they 
encounter antigen (before naïve T cells develop into effector CD4+ subsets). TCM are believed 
to be maintained during infection, and their ability to turn in to effector cells upon secondary 
stimulation make them important mediators of long-term protective immunity (118). 
 
Effector memory T cells, TEM, show a significant production of for example IFN-γ and other 
cytokines but lack the CCR7 surface marker (and are CD62L
lo
) (58). These cells express 
recepors for homing to inflamed tissues and are also believed to express CD45RO+CD28+, 
like the TCM population. Effector memory T cells are surviving T cells that are derived from 
naïve T cells after primary antigen contact and after subsequent differentiation into different 
effector CD4+ T cell subsets. 
 
Both TCM and TEM are found in the blood, however, TCM are predominant in the CD4 
population (reviewed in (59)). 
 
Terminally differentiated T cells lack CD27 and CCR7 (described in (85)). 
 
The cytokine production seems increase profoundly as cells differentiate to a CCR7- 
phenotype (119)(102). A model has been proposed for the CD4+ T cell differentiation, 
explaining the correlation between memory status (represented by the expression of CCR7) 
and effector functions (represented by the production of IFN-γ, TNF and IL-2), see figure 1.5. 
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The long-term memory potential is greatest among the TCM population, and effector function 
peaks as CCR7- expression is lost and CD4 T cells simultaneously produce all three effector 
cytokines. 
 
 
Figure 1.5 Model for CD4+ T cell differentiation and correlation with cytokine production. Upon 
antigenic stimulation, naïve CD4+ T cells differentiate and progressively gain effector functions until they 
reach a peak where they simultaneously produce all three cytokines IGN-g, TNF and IL-2. Up until them, 
cells are CCR7+ and inhibit a central memory phenotype where the long-term memory potential is high. 
From this point, the cells lose CCR7 expression and are characterized by an effector memory phenotype. 
Cytokine production and long-term memory potential is gradually lost and cells are finally terminally 
differentiated (producing only IFN-γ) before they undergo apoptosis. Figure from (120).   
1.5 HIV 
 
HIV (human immunodeficiency virus) is a retrovirus affecting the immune system. It is 
transmitted primarily through sexual contact, but also during sharing of needles or blood 
transfusions. Mother-to-child transmittance also occurs. 
 
Even though antiretroviral treatment may slow down disease progression, no cure is yet 
available, and since its discovery early in the 1980s (121)(122), it still remains a huge global 
health problem. According to WHO (123), 34 million people are living with HIV (2011), and 
in the same year, a total number of 1.7 million deaths were registered worldwide due to AIDS 
(123). In addition, there were a significant number of 2.5 million individuals newly infected 
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with HIV. Although this is recognized as a global problem, the majority of the individuals 
infected are located in Sub-Saharan Africa. 
 
Cell entry by virus particles is mediated through interactions between a viral envelope protein 
and CD4 via the chemokine receptor CCR5. HIV RNA and enzymes are transferred to the 
host cell (e.g. CD4 T cell or DC), making the virus able to replicate within the host. Virus 
particles are later released as virions that are able to infect new cells (124). The increase in 
blood-borne virus particles is associated with a depletion of the CD4 T cell population. In 
addition, cytotoxic CD8 T cells are activated. The reason for the rapid and progressive CD4 T 
cell depletion is not well understood, although the killing of infected cells by CTLs may 
contribute to this. Other direct or indirect cytopathic effects are also proposed as possible 
explanations (125). HIV disease also cause an increase in the T cell turnover (126). 
 
Although HIV cannot be cured, the introduction of highly active antiretroviral therapy 
(HAART) has had a significant impact in HIV medicine. HAART inhibits HIV replication 
and is associated with a rapid increase in CD4 numbers in patients with advanced disease 
(127). 
 
HIV positive individuals are more susceptible to tuberculosis than HIV negative, most likely 
because HIV causes a depletion of the CD4 T cell population, a statement supported by the 
fact that patients with a low CD4 count are more prone to tuberculosis infection than patients 
with a higher count (128). There is also a correlation between the CD4 T cell count and the 
reactivation of LTBI (reviewed in (129)). The increased susceptibility remains, even after 
treatment with HAART (130). It is speculated that the quality of the restored CD4 T cell 
population does not resemble that of healthy individuals. Polyfunctionality of the T cells, i.e. 
the ability to produce more than one mycobacteria-specific cytokine in response to 
stimulation (see 1.6.1) or the memory phenotype of the T cells (see 1.6.2) may be altered, 
leading to an impaired immune response towards tuberculosis. 
  
Introduction 
___________________________________________________________________________ 
 
25 
 
1.6 HIV- MTB co-infection 
 
The HIV/tuberculosis combination is potentially lethal and the risk of active tuberculosis is 
increased more than a 100-fold in those with HIV. 14 million people worldwide are believed 
to suffer from this co-infection (131), and it kills 430 000 of these individuals every year (1). 
Knowledge on how these two diseases are intertwined and affect each other in a negative 
manner, is essential to understand how they can be controlled, and how death due to 
tuberculosis can be avoided in HIV patients. 
 
Co-infection accelerates the deterioration of the immunological functions leading to 
subsequent death if left untreated. However, the reasons this happens are debated (reviewed in 
(132)). This part focuses on the two most important aspects for this work; how mycobacteria-
specific cytokine production is affected in HIV positive individuals, and how HIV alters the T 
cell memory phenotype and how this can influence the host response against mycobacterial 
infections. 
1.6.1 CD4+ T cell effector functions in HIV infection 
As was earlier elucidated (section 1.4.3), IFN-γ, TNF and IL-2 are important CD4+ T cell 
effector cytokines to defend the host against mycobacterial infection. Polyfunctional CD4 T 
cells producing two or more of these are believed to be of great importance to the immune 
system's ability to contain tuberculosis infection. However, the ability of the CD4 T cells to 
produce two or more cytokines seem to decrease with increasing viral load (95). The same 
study found that in HIV disease, IL-2 seemed to be lost first, followed by TNF and at last, 
IFN-γ production. 
 
Studies have revealed that the proportion of cytokine-producing mycobacteria-specific CD4 T 
cells is smaller in HIV positive individuals than in HIV negative individuals (133). This in 
contrast to other studies, claiming that HAART reconstitutes the mycobacteria-specific 
response of CD4 T cells (134)(135). Others again claim the IFN-γ secreting capacity is 
impaired during HIV infection (136)(137). 
 
Polyfunctionality is also believed to be impaired during HIV infection (133)(138), however, 
some claims it can be restored during HIV therapy (106). 
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There has been reported that during therapy there is a dynamic relationship between the 
cytokines being produced (IFN-γ and IL-2 are the ones investigated), and shifts between what 
cytokine is the prominent one may occur (139). 
 
1.6.2 Memory T cells in HIV infected individuals 
Memory T cell populations can be phenotypically characterized using a combination of 
surface markers, like described earlier in this section (1.4.4). The chosen parameters were 
CD45RO, CD27, CD28, CD57, PD-1, HLA-DR and CCR7. Earlier studies have shown that 
IFN-γ producing CCR7- T cells are highly concentrated in the pleural fluid of tuberculosis 
patients (140). Not much is known about whether or not, and how, co-infection with HIV 
alters the memory phenotype. 
 
Therapy in HIV patients is believed by some to increase the polyfunctionality of the CD4 T 
cells. The newly generated CD4 T cell population consists of mainly effector memory cells 
simultaneously producing TNF and IFN-γ. This implies that HIV therapy should reduce 
susceptibility to MTB. This is not always the case, however (see 1.5). Central memory CD4+ 
T cell responses have been found not to be restored by HAART (141). In SIV infection (the 
HIV equivalent in non-human primates) it was found that memory CD4+ T cells are lost 
(142). 
 
Not much is known about the memory population in HIV infected individuals and how this 
affects the immune response towards tuberculosis. It is reason to believe that therapy skews 
the memory phenotype, and that this leads to impaired response in HIV patients 
(112)(133)(143)(144)(145)(146)(147). This study hopes to investigate these matters. 
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2. Aim of study 
 
Onset of antiretroviral therapy can stop the decline of CD4+ T cells in HIV-patients and 
restore the CD4+ T cell population. But for unknown reasons, HIV-patients show, even at 
relatively normal T cell counts, increased susceptibility to mycobacterial infections (section 
1.5). We hypothesize that polyfunctionality (simultaneous production of several effector 
cytokines, 1.4.3 and 1.6.1) of anti-mycobacterial CD4+ T cell responses as well as changes in 
the memory T cell subset composition (1.4.4 and 1.6.2) might be involved in this impaired 
response against mycobacteria of HIV-patients. 
 
The main aim of this study was therefore to establish and apply protocols to investigate anti-
mycobacterial CD4+ T cell effector functions and memory T cell composition HIV-infected 
individuals and compare them with healthy controls. 
 
Specific objectives were: 
 
 To establish a protocol for isolation of PBMCs from heparinized peripheral blood 
samples from healthy control subjects as well as HIV positive patients at the indoor 
clinic at St. Olavs hospital under a BL3 protocol. 
 
 To test the effect of long-term cryopreservation of PBMCs on the quality of anti-
mycobacterial T cell effector functions. 
 
 To design a multicolor flow cytometric staining panel allowing analysis of 
mycobacteria-specific CD4+ T cell effector responses as well as memory T cell  
phenotyping from the same sample.
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 To establish, optimize and apply an in vitro assay to stimulate PBMCs from HIV 
patients and healthy donors with mycobacterial antigens from M.avium (heat-killed 
M.avium and M.avium PPD) and M.tuberculosis (MTB PPD). After overnight 
stimulation, T cells should be analyzed by multicolor flow cytometry for: 
 
o Frequency of M.avium and M.tuberculosis-specific CD4+ T cells in PBMCs 
from HIV patients and healthy controls 
 
o Polyfunctionality of this T cell response (simultaneous production of the three 
cytokines IFN-γ, TNF and IL-2). 
 
o T cell phenotyping of mycobacteria-specific as well as total CD4+ and CD8+ 
T cells for memory T cell status markers.   
 
 Cytokine production of PBMCs stimulated with mycobacterial antigens should be 
verified using additional methods such as PCR and ELISA. 
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3. Materials and methods 
 
In short, this project comprises the analysis of host effector mechanisms in healthy donors 
versus HIV positive patients towards infection by Mycobacterium tuberculosis. HIV patients 
are immunodeficient and are prone to opportunistic infections by agents such as 
M.tuberculosis. Study of CD4 T cells were the main focus, as they are depleted in HIV 
patients, and at the same time are the main weapon against mycobacterial infections. Such 
analysis is best performed using fluorescent antibodies and detection by flow cytometry. In 
addition to analysis by flow cytometry, PCR and ELISA were performed. 
 
This part of the work describes how analysis of blood samples from healthy donors as well as 
HIV patients was performed. Included is the build-up of the study, the processing of samples, 
and descriptions of methods used (flow cytometry, PCR and ELISA) as well as a discussion 
regarding the ethical issues of using patient samples. Focus will be on flow cytometry, as this 
was the main technique used. 
3.1 Study build-up 
As a start for the whole project, healthy donors were recruited from the staff at IKM, NTNU. 
All donors except one had received a BCG vaccine in their late childhood. None of them had 
ever experienced any signs of tuberculosis, however none had been tested for the disease. 
They were all assumed to be HIV negative, although never tested.  
 
The contributors donated a volume of between 15 and 30 mL of heparinized blood. Peripheral 
blood mononuclear cells (PBMCs) were isolated using ficoll density gradient centrifugation 
as described in Appendix 1. 
 
Some of the isolated cells were used immediately and were stimulated with three different 
mycobacterial agents, as described in 3.2.2. After stimulation, they were stained for 
extracellular markers (see 3.3.5) and intracellular for cytokine production (see 3.3.6), and it 
was proceeded with flow cytometry. Additional methods used to describe cytokine profile 
were PCR (Polymerase chain reaction) and ELISA (Enzyme-linked immunosorbent assay). 
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The rest of the white blood cells were cryopreserved as described in 3.2.2, some in -80 °C and 
some in liquid nitrogen. At a later stage, some were thawed and stimulated to compare results 
of frozen cells with those of fresh cells. 
 
For the patient part of the study, HIV positive patients were recruited from the indoor clinic at 
St. Olavs Hospital, Trondheim, where they visit on a regular basis for controls and follow up. 
Professor Jan Kristian Damås coordinated the recruitment of HIV positive donors. 
 
A total number of seven patients agreed to each grant between 15 and 25 mL heparinized 
blood. 
 
Isolation of white blood cells from HIV patients was performed as described in 3.2.1 (exact 
protocol in Appendix 1), and they were stimulated as described in 3.3.2. They were analyzed 
based on the same criteria as the healthy donors and by the same methods (only flow 
cytometry and PCR were used for the HIV patients). 
 
A biobank was established based on the blood samples from the HIV patients. White blood 
cells were isolated, and preserved in cryotubes in liquid nitrogen. Samples were anonymized 
but linked to a spreadsheet containing information on age, sex, ethnicity, CD4 T cell count, 
viral load, medicine information and so on. At another location on the hospital, plasma and 
serum samples from each patient were also stored. The purpose of the biobank was to 
establish a starting point for further analysis of HIV patients' immune effector mechanisms. 
 
Table 3.1 includes some vital facts about the recruited HIV patients. 
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Table 3.1: HIV patient characteristics 
ID Amount blood 
received 
PBMCs 
isolated (• 106) 
Age Sex HIV-RNA 
(copies/mL) 
CD4 count 
(cells/μL) 
H001 18 mL 14 33 M 120 70 
H002 15 mL 10,6 26 F 70 370 
H003 15 mL 5,4 43 M <20 220 
H004 20 mL 14,4 33 F <20 450 
H005 20 mL 20 34 F <20 550 
H006 25 mL 13 42 M <20 570 
H007 20 mL 9 37 M <20 340 
 
3.2 Processing of blood samples 
 
3.2.1 Isolation and counting of peripheral blood mononuclear cells 
(PBMCs) 
Sodium heparin tubes were used to acquire blood samples. Heparin is an anticoagulant that 
prevents clotting of the blood from sampling to further processing. As samples are processed 
within short time from sampling, using the mild anticoagulant heparin is sufficient. 
 
The principle behind the isolation of PBMCs from whole blood is the separation of 
components through a density gradient. For a complete description of the protocol, refer 
Appendix 1. The protocol is an modification of a protocol routinely used in the research group 
for isolating PBMCs from buffy coats. A modification is necessary because heparinized blood 
contains much less cells than a buffy coat, and therefore requires less washing steps. 
 
The blood samples were diluted at a 1:1 ratio with PBS (Sigma), and 30 ml of blood/PBS 
were carefully layered on top of 15 mL Lymphoprep solution (Axis-Shield PoC). 
Lymphoprep is a reagent developed especially for the purpose of isolating white blood cells, 
and it contains polysaccharid and sodium diatrizoate (148). It has a density that just exceeds 
water (namely 1.077 g/mL), and centrifugation at 1800 rpm for 20 minutes yields a solution 
where heavy erythrocytes pass through the medium and are collected at the bottom of the 
tube. Plasma has a low density and will stay in the top of the tube, over the Lymphoprep. At 
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the plasma/Lymphoprep interface, a ring of white blood cells is formed. This ring can easily 
be harvested by a sterile pipette and transferred to a new tube for washing and purification. 
 
After washing the isolated white blood cells twice (800 rpm for 8 minutes, then 1400 rpm for 
6 minutes) in HANKS balanced salt solution (Sigma), the cells were resuspended in 5 mL 
culture medium. As culture medium, RPMI (Sigma) is supplemented with human serum as a 
source of nutrients for the living cells. 2 % serum is sufficient for short-term handling of the 
cells, whereas 10 % is required for overnight stimulation of T cells. L-glutamine is used for 
amino acid supplement in culture medium (149), and HEPES is a buffer that makes the 
medium exhibit an effective buffering in the physiological range (150). 
 
As cells are adequately purified, they need to be counted before further work is continued. 
Several methods are available for quantification of cells, among the most widely used in this 
lab is the coulter counter based on the electrical resistance of the cells, counting in a burker 
chamber in a microscope and the Countess automated cell counter (Invitrogen) based on a dye 
exclusion principle exhibited by trypan blue. Using the Countess automated cell counter is a 
fast way to determine cell concentration in solution, and it is believed to be both accurate and 
precise (151). Based on this information, this was the preferred method of counting cells in 
this project. 
 
The Countess automated cell counter utilizes the fact that trypan blue is selectively able to 
distinguish between live and dead cells and combines this with an accurate image analysis to 
provide information on cell concentration and cell viability in a sample. Live cells have intact 
cell membranes, and therefore exclude dyes like trypan blue. Dead cells, however, are not 
able to exclude the dye, and the color is taken up in the cell. For counting, 10 μL trypan blue 
is mixed with 10 μL sample. The two are mixed and 10 μL transferred to a glass counting 
chamber. As the chamber is inserted into the device, an image is constructed where live cells 
appear with a colorless cytoplasm, whereas dead cells have a dark appearance. As fine 
adjustments are made, the machine is then able to analyze the picture and elucidates 
information on the sample. 
 
After counting, cells are stimulated or frozen for long-term storage, see below. 
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3.2.2 Biobanking of WBCs 
Long-term storage of patient samples may be beneficial for more reasons than one. This will 
make it possible to establish a biobank that can be utilized for several research purposes now 
and later. Several patient samples may be analyzed simultaneously to reduce the possibility of 
variations between independent experiments. In this project, cryopreservation up to three 
months of healthy donor samples was performed to decide whether or not this is a suitable 
method for storing of HIV patient samples. 
 
Cryopreservation of cells is a method for long-term storage with minimal damage to 
intracellular structures and effector functions. At sub-zero temperatures, intracellular activity 
is paused, and cells are believed to retain their functionality at thawing. 
 
For this project specifically, the most critical aspects of cryopreservation is the viability after 
freezing and the effect of cryopreservation on cytokine production. As a limited number of 
cells are available, it is essential that viability does not drop too far. Additionally, good and 
careful freezing and thawing protocols will assure that cells are affected as little as possible 
from cryopreservation and that characteristics such as cytokine production in response to 
stimuli are similar as for fresh cells. Although live cells are distinguished from dead ones in 
the flow cytometer based on a live/dead stain procedure, optimal analysis of cells and their 
effector functions depend on a great proportion of cells being alive and healthy. 
 
Earlier studies have shown that viability does not decrease much even after cryopreservation 
up to 12 years (152). Others report on a decrease in viability (153), and some points to that 
high viability depends on an optimal freezing/thawing protocol (154). 
 
To ensure the best possible conditions for the cells during cryopreservation, it is critical that 
the freezing and thawing are performed in a controlled way. Freezing rate is ideally kept at 
one degree/minute, to avoid too much intracellular ice crystal formation (155). The rate-
controlled freezing device Mr Frosty (Nalgene) was used in this project. Isopropanol alcohol 
inside the box ensures the correct rate of cooling as the device is stored in -80 °C. After 24-72 
hours, individual cryotubes can be moved from Mr Frosty to containers of liquid nitrogen, 
keeping the temperature at -196 °C. Thawing should be rapid, again to avoid intracellular ice 
crystal formation. 
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20 % dimethyl sulphoxide (DMSO) in fetal calf serum (FCS) was used as freezing medium. 
Up to 7.5 • 106 PBMCs were resuspended in 0.5 ml pure FCS. Then 0.5 mL of the 20 % 
DMSO/FCS freezing medium was carefully added, resulting in a final concentration of 10 % 
DMSO. Cryotubes were immediately transferred to Mr. Frosty and stored  a -80 °C freezer 
until moving to liquid nitrogen (for a complete description of the protocol, refer Appendix 2). 
DMSO is known to be toxic to the cells, but is nevertheless used as a cryoprotective agent. At 
cooling to low temperatures, DMSO is integrated into cell membranes and thereby inhibit the 
formation of ice crystals (156). To avoid DMSO from exerting toxic effects to the cells, and 
hence creating stress to the cells, mixing of the freezing medium and the cells must be gentle. 
 
Different studies have proposed varying views on the effect of cryopreservation on cytokine 
secretion (156)(157)(158). Some results indicate that cytokine production is not at all affected 
by freezing and thawing, whereas others report on a four to fivefold decrease. This verifies 
how a careful protocol for freezing and thawing is absolute necessary to have the PBMCs 
retain their effector function after cryopreservation. 
 
After samples are frozen, they are either preserved for long-term storage or they are thawed 
after a while and analyzed for effector functions after stimulation, see below. 
3.2.3 Stimulation of WBCs 
Upon encountering antigen, the T cells specific for the antigen present will be activated and 
start to divide. This leads to a population of T cells that is able to exert specific effector 
functions that aim at fighting infection. This project was mainly performed using short 
(overnight) stimulation. Total percentage of specific T cells is therefore low. 
 
Facilities for handling live Mycobacterium tuberculosis are not available at IKM as of now. 
Instead, M.avium is often used as a model organism for M.tuberculosis (32). M.avium itself 
may be pathogenic, but is not considered to be as harmful as M.tuberculosis and can be 
handled under BL2 conditions. 
 
Stimulation is therefore performed using heat-killed M.avium. In addition, cells are stimulated 
with purified protein derivative (PPD) from M.avium and M.tuberculosis (kind gift from 
Ingrid Olsen, Norwegian Veterinary Institute, Oslo), respectively. PPD consists of purified 
parts (i.e. antigens) of bacteria that function as immunogens, they are thus able to mount an 
Materials and methods 
___________________________________________________________________________ 
35 
 
immunologic response in host cells. PPD can be prepared by growing bacteria in medium, and 
then collecting the supernatant. Proteins are present in the supernatant and may be further 
purified using for example chromatography (159)(160). Even though results using a heat-
killed close relative and PPD from the close relative and the tuberculosis bacteria itself may 
not be completely realistic, it is hope that the results may later be confirmed using live 
M.tuberculosis. 
 
Stimulation for later flow cytometric assays was performed in flat bottom 96-well plates. To 
each well is added 0,5 • 106 cells, to a total volume of 200 μL per well (RPMI 10 % A+ is 
used as culture medium). Tests with different numbers of PBMCs per well were performed 
(see 4.1.3), and in the low range it is hard to obtain satisfying number of cells when aiming 
for the count of total 50 000 cells per analysis in the flow cytometer. Stimulation for PCR and 
ELISA was carried out in flat bottom 48-well plates (1,25 • 106 cells – 500 μL). 
 
Stimulating agents are distributed to the cells as described in Appendix 2. Stimulation was 
always performed in duplicates, and negative and positive controls were always included. As 
negative control, some wells were unstimulated. As positive control, Cell stimulation cocktail 
500x (eBioscience) was used. Cell stimulation cocktail consists of several substances, 
including phorbol 12-myristate 13-acetate (PMA) and ionomycin that stimulate the 
production of cytokines. PMA is a structure analogue to diacylglycerol, a substance known to 
allosterically activate protein kinase C (PKC). Activation of PKC triggers a cascade of events, 
resulting in T cell activation (161). PMA is known to downregulate CD4 expression (162). 
Ionomycin is an ionophore that synergizes with PMA in the activation of PKC, by raising the 
intracellular levels of calcium ions (163). 
 
Costimulatory signal was also added to the wells prior to stimulation. Costimulatory 
molecules are one out of two required signals for T cell activation, and are usually present on 
antigen-presenting cells that deliver the other essential signal for activation, association 
between MHC molecules and antigen-derived peptides. To ensure activation of antigen-
specific T cells, anti-CD28 (eBioscience) and anti-CD49d (BioLegend) are added (1 μg/mL). 
 
Cells are stimulated in 37 °C overnight and to a total of approximately 16 hours. When cells 
are to be used for flow cytometric assays, Protein transport inhibitor cocktail 500x 
(eBioscience) is distributed to the cells. This cocktail contains a mixture of substances that 
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inhibit the transport of newly produced cytokines from the ER to the Golgi and ultimately the 
transport out of the T cell into the surroundings. This is essential for the analysis of each 
individual T cell and the cytokines produced from it. As manufacturer's guidelines is vague on 
how the transport inhibitor should be distributed to the cells, experiments were conducted, 
results can be read later on in this thesis (see 4.1.2). Unless otherwise stated, protein transport 
inhibitor cocktail was added after 16 hours and left to work for four hours. 
 
The next step involves extracellular and intracellular fluorescent staining (for flow cytometric 
assays) or cell lysis and supernatant harvesting for PCR and ELISA, respectively. 
 
3.3 Flow cytometric analysis 
 
3.3.1 Introduction to flow cytometry 
Flow cytometry refers to the technique of measuring physical and/or chemical characteristics 
of cells or other particles while they flow past a laser one by one. Utilization of fluorescence 
in cell quantification, and the subsequent development of flow cytometers accelerated in the 
1960s, and one of the first reports describing fluorescence flow cytometry was written by van 
Dilla and collegues in 1967 (164). 
 
In today's instruments, a sample in solution is inserted to the flow cytometer and 
hydrodynamic focusing produces a stream of single particles. Light scattering from each cell 
is measured and provides important information about the cell's properties. Light that is 
scattered in the forward direction, that is at low angles from the laser beam's axis, is focused 
by a lens and detected by a forward scatter detector (FSC). This detector supplies information 
about the size of the cell, and can be used to distinguish between for example T cells 
(relatively small) and macrophages (big in comparison). Light scattered at an angle of 90 
degrees is detected by the side scatter detector (SSC) and provides an understanding of the 
cell's granularity. Granulocytes have a higher SSC signal than lymphocytes that are agranular. 
The principles behind the flow cytometer optics are shown in figure 3.1. 
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Figure 3.1: The principle behind the optics of a flow cytometer. Cells flow in a stream of single particles, 
and are illuminated with light from different lasers. Light scattered in the forward direction is focused by 
a lens and detected by a forward scatter detector (FSC), whereas light scattered at 90 ° is detected by the 
side scatter detector (SSC). The flow cytometer can also detect fluorescence as cells are illuminated with 
laser light and fluorochromes emit light at different wavelengths. Detectors and filters sense the emitted 
light and signals are sent (via photomultiplier tubes) to a computer and a software that interpret them and 
give an output characterizing the sample. Figure from (165). 
 
Fluorescence measurement is a useful and important application of flow cytometry. 
Antibodies to cell components (intracellular or extracellular) may be labeled with a 
fluorescent tag and different detectors inside the flow cytometer detects emitted light from 
these fluorochromes as they are illuminated with light from a laser. Different channels with 
filters letting through light only of a specific wavelength make it possible to detect light from 
several different fluorochromes at once, as long as they are matched not to overlap in 
emission spectra. Multicolor flow cytometric assays are the main subject for this project. 
 
 
For this project, a BD LSR II flow cytometer was used. This bench-top flow cytometer has 
four lasers and different filter combinations makes detection of up to 16 fluorochromes at the 
same time possible. The different lasers and possible combinations are listed in table 3.2. 
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Table 3.2: Lasers and corresponding filter combinations for the BD LSR II flow cytometer. 
Laser Filter combination 
Violet, 405 nm 780/60 
705/70 
610/20 
525/50 
450/50 
Blue, 488 nm 685/35 
585/42 
525/50 
Yellow/green, 561 nm 780/60 
710/50 
670/14 
610/20 
585/20 
Red, 640 nm 780/60 
710/50 
670/14 
 
11 out of 16 filter combinations were used simultaneously in this project (see 3.3.5/3.3.6). 
 
3.3.2 Compensation 
When it is necessary to measure more than one cell characteristic, and thus more than one 
fluorochrome, at once, an investigation of the spectral overlap between the different 
fluorochromes is important. Each individual fluorochrome emits light over a fairly broad 
range of wavelengths, and there is a risk of two or more fluorochromes overlapping in their 
emission spectra. This creates a spillover in the neighboring channels, thus making the true 
measurement from each signal difficult. Spectral overlap between two fluorochromes A and B 
detected in the two channels FL-1 and FL-2, respectively, is illustrated in figure 3.2 below. It 
can be seen from the figure that a measurement of the signal from FL-1 mostly consists of 
signal from fluorochrome A, but a small part of the total signal is due to fluorochrome B as 
well. 
 
Materials and methods 
___________________________________________________________________________ 
39 
 
 
Figure 3.2: Illustration of spectral overlap between two fluorochromes and spillover into neighboring 
channels. A is measured in the FL-1 channel and B in the FL-2 channel. Dark blue shade represents the 
proportion of B that overlaps into the FL-1 channel. Red shade represents the proportion of A that 
interferes with FL-2 channel measurements. Compensation corrigates for this. Figure from (165). 
 
To minimize errors due to spillover into neighboring channels, it is essential to compensate 
for these overlaps. Compensation is ultimately performed inside the software, and is a 
calculation of the percentage interference a fluorochrome will give in all other channels 
except the one where it is assigned to be measured. 
 
To be able to calculate the overlap, each fluorochrome was run through the flow cytometer 
alone, meaning with no other fluorochromes present. Instead of using a cell-based 
compensation, bead-based compensation was performed. Beads (BD CompBeads) are 
spherical particles that bind fluorescently tagged antibodies, resulting in beads labeled with a 
single colored antibody bound. 
 
When beads are run for all fluorochromes, the FACS Diva Software calculates a 
compensation where the spillover from any other channel is subtracted from each color. 
 
3.3.3 Controls 
Including relevant controls is essential for multicolor flow cytometric assays, and especially 
when staining for intracellular cytokines that are usually present in small amounts. Well-
Materials and methods 
___________________________________________________________________________ 
 
40 
 
separated populations are not always obtained, and distinguishing between negative and 
positive populations may be hard. So-called isotype controls are often included as negative 
controls. These controls are fluorochrome-specific and isotype control samples contain cells 
and isotype controls for the fluorochrome of interest. The isotype control antibody does not 
recognize an epitope that is expressed by the cells in the sample, but is coupled to the same 
fluorochrome and can in this way help decide if a positive signal from the stained sample is a 
true positive signal or just the result of unspecific binding between cells and fluorochrome. It 
is important that the isotype controls have the same characteristics as the specific antibodies 
in analysis; from the same species, in the same concentration, and of the same 
immunoglobulin class (isotype). The latter is due to avoid signal from unspecific binding 
between antibody and Fc receptors. 
 
It is claimed that isotype staining may not be the best way to identify gating boundaries (166), 
especially when considering intracellular staining, and that other controls should be included 
as well. One possibility is to use a method called Fluorescence minus one (FMO), where all 
fluorochromes in the panel except one is included for each control (167). Then, the difference 
in signal between the actual sample and the FMO control represents the positive events, and 
the information can be used to set the gating. As controls ideally are chosen changing one 
parameter at a time, FMO may be a better choice than isotype controls. 
 
Like earlier mentioned, controls were also included for the stimulation itself. Unstimulated 
samples will show signal from all the extracellular markers, but they should not have any 
cytokine-producing populations. As positive controls, cell stimulation cocktail with PMA 
upregulate the cytokines, and these controls show great cytokine production if the experiment 
is successful. As a control, samples were also run in duplicates. 
 
3.3.4 Colors 
Colors were chosen based on a number of criteria. The total number of fluorochromes that can 
be detected simultaneously in a multicolor flow cytometric assay depends on the number of 
lasers and detectors and filters in the flow cytometer. The BD LSR II flow cytometer used in 
this project has four different lasers (blue, red, violet and yellow/green), and various filter 
combinations makes detection of up to 16 colors possible (refer chapter 3.3.1). 
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What was important for this study, can be summed up in three points: 
 The possibility of distinguishing CD4 T cells from the rest of the cell population 
 The detection of cytokines produced from these CD4 T cells 
 The presence of surface markers that determine the differentiation of CD4 T memory 
cells 
 
As all T cells express CD3, this marker was included to identificate the T cell population from 
the rest of the PBMCs. CD4 and CD8 are also stained to identify CD4+ and CD8+ subsets. A 
viability dye (eBioscience Fixable viability dye eFluor 780) was included that irreversibly 
stains dead cells to exclude them from analysis. The principle behind the protocol is that 
compromised membranes of dead cells are permeable to the viability dye and cause a strong 
fluorescence. 
 
Detection of IFN-γ, TNF and IL-2 effector cytokine production from T cell subsets in 
response to stimulation with mycobacterial antigens were chosen as read-out to detect 
mycobacteria-specific T cell frequencies. These cytokines are assumed major effectors of 
mycobacteria-specific CD4 T cells, and are well-documented (see 1.4.3) choices for T cell 
analysis in tuberculosis-related research. 
 
In addition, a set of surface markers allowing for memory T cell differentiation status analysis 
were chosen; CD27, CD28, CD45RO, CD57, PD-1, CCR7 and HLA-DR. 
 
The actual choice of fluorochromes was established at the beginning of the project and 
optimized during the work. Ideally all fluorochromes in a panel should be stable, bright and 
stain the markers effectively. This is not always achievable in a multicolor assay, and 
compromises must often be made. For example, it may be a good idea to choose the brightest 
and most stable colors for the markers that are least expressed and have the least difference 
between their positive and negative populations. 
 
Brightness can be defined using a so-called staining index. Using the same antibody 
conjugated to different fluorochromes and comparing their stain indices, their relative 
brightness may be considered. For example, PE has an average stain index of 302, being one 
of the brightest fluorochromes. APC is next with 278, whereas Alexa Fluor 700 has a staining 
index of 61, and FITC has 56 (168). 
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To stain for the effector cytokines TNF, IFN-γ and IL-2, fluorochromes like APC, eFluor450, 
BV421 and PE were obvious choices as these colors cause a bright fluorescent signal. For 
identification of major populations like CD3, CD4 and CD8, less bright colors are usually 
sufficient, since these epitopes are highly expressed on the cells (168). When stability is 
considered, most single dyes are stable and retain their fluorescent activity for quite some 
time after staining. However, to increase the maximum number of detectable markers, tandem 
dyes have been developed. Tandem dyes utilize the advantages of two separate dyes and when 
the first dye is excited, all energy is transferred to the second dye that causes the fluorescence 
from its emission. Such dyes are often sensitive to photoinduced degradation and light 
exposure and exposure to paraformaldehyd (fixating agent) must be minimized. It would be 
ideal to avoid the use of unstable dyes, but it is sometimes necessary. 
 
Careful consideration was made not to choose colors that were non-compatible with one 
another regarding spectral overlap. Several online web tools are available for this purpose, for 
example BioLegend Multicolor Panel Selector. This tool allows the selection of compatible 
colors and gives a notice when colors cannot be combined. 
 
The BioLegend Fluorescence Spectra Analyzer even illustrates the emission spectra overlap, 
and figure 3.3 below shows the emission of a selection of the colors used in the study 
(BV421, BV510, BV605, BV785, Alexa Fluor 700, eFluor450, APC, PE). 
 
Materials and methods 
___________________________________________________________________________ 
43 
 
 
Figure 3.3: Emission spectra of fluorochromes BV421, BV510, BV605, BV785, Alexa Fluor 700, 
eFluor450, APC and PE. Image constructed using BioLegend Spectra Analyzer that may be utilized to 
ensure selected fluorochromes are compatible. Figure from (169). 
 
The figure shows that emission maximum peaks at different wavelengths, and these colors are 
therefore compatible and can all be used in the same multicolor assay. The fact that there is 
some overlap between the spectra is almost inevitable, and can be corrigated for using 
software compensation (see 3.3.2). 
 
3.3.5 Extracellular staining of PBMCs 
A more detailed protocol of how the extracellular and intracellular staining was performed, 
can be read in Appendix 2. 
 
After overnight stimulation, cells are transferred to 12 × 75 mm polystyrene tubes and 
extracellular antibodies conjugated to fluorescent dyes are distributed to the cells at a 
concentration of 5 μl/1 mL (meaning 1 μl was added to each well in the 96-well plate 
containing 200 μL of sample) and are left in the dark to work for 15 minutes. For the HIV 
study, the staining was performed using fluorochromes as described in table 3.3. Surface 
markers like these, especially CD3, CD4 and CD8, are relatively easy to identificate, and they 
were therefore analyzed using less bright colors (refer 3.3.4). It should also be noted that 
fluorochromes BV421 and eFluor450 are non-compatible, meaning CD57 and CCR7 cannot 
be stained for simultaneously. 
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Table 3.3: Extracellular staining. The epitopes, fluorochromes, manufacturers and laser and filter 
combinations are shown. 
Epitope Fluorochrome Manufacturer Laser Filter 
combination 
CD3 BV785 BioLegend Violet, 405 nm 780/60 
CD4 BV711 BioLegend Violet, 405 nm 705/70 
CD8 Alexa700 eBioscience Red, 640 nm 710/50 
CD27 BV510 BioLegend Violet, 405 nm 525/50 
CD28 PE/Cy7 eBioscience Yellow green, 561 nm 780/60 
CD45RO FITC eBioscience Blue, 488 nm 525/50 
CD57 eFluor450 eBioscience Violet, 405 nm 450/50 
CCR7 BV421 BioLegend Violet, 405 nm 450/50 
PD-1 BV605 BioLegend Violet, 405 nm 610/20 
HLA-DR APC eBioscience Red, 633 nm 670/14 
 
Dyes were washed away, and a live/dead stain followed. Fixable viability dye eFluor780 
(eBioscience) penetrates the damaged membranes of dead cells and in this way they can be 
excluded from further analysis. 
 
After extracellular staining, cells were fixed in a 2 % solution of paraformaldehyd (PFA) in 
PBS. Fixation terminates every biochemical reaction going on in the cells, and thereby 
preserves them in a fixed state. Several fixation methods are available, among them 
paraformaldehyd that fixate cells by crosslinking proteins. 
 
3.3.6 Intracellular staining of PBMCs 
For the intracellular staining, cells need to be permeabilized. The protein transport inhibitor 
used, prevents cytokine release from the cells, but the stain needs to enter the cells and bind to 
cytokines there. As a permeabilizing agent, 0,5 % saponin in PBS was used. Treatment with 
saponin detergent creates small pores in the cell membrane where dyes are able to pass. 
 
Intracellular stain was added to the cells in the same concentration as extracellular dyes, 1 
μl/test (2 μg/mL). As an experiment, it was tested to modify this dose, and results showed that 
this concentration should not be lowered (see 4.1.4). 
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All HIV samples were divided in two sets after stimulation, and one set was stained 
intracellularly with all three cytokine antibodies using the same fluorochrome (PE). PE is a 
very bright fluorochrome, and therefore a good choice for identification of cytokines from a 
small number of mycobacteria-specific T cells (refer 3.3.4). By staining all three cytokines 
with the same fluorochrome, cytokine-producing T cells can be identified in one single 
channel and this allows for the use of other channels for additional T cell markers. 
 
To see if cells produce one, two or all three cytokines, the second set of cells from HIV 
patients were stained with different colors (table 3.4) and less surface markers. All chosen 
fluorochromes are very bright and well-suited for identification of cytokines. 
 
Table 3.4: Staining protocol for identification of CD4 T cell polyfunctionality 
Epitope Fluorochrome Manufacturer Laser Filter 
combination 
IFN-γ PE BioLegend Yellow green, 561 nm 585/20 
TNF BV421 eBioscience Violet, 605 nm 450/50 
IL-2 APC eBioscience Red, 633 nm 670/14 
 
The exact protocol and staining and stimulation panel for extracellular and intracellular 
staining can be found in Appendix 2 and Appendix 3, respectively. 
 
After these staining procedures, cells were ready for flow cytometric analysis. 
 
3.3.7 Flow cytometric analysis 
Cells were analyzed using a BD LSR II Flow Cytometer and BD FACSDiva software. 
 
The flow cytometer was connected to a computer and FACSDiva software opened. For each 
sample, 50 000 (or 80 000 – 100 000 for HIV samples) cells were analyzed, and the FCS 
threshold was set to 20 000. 
 
When starting an experiment with new colors, compensation was required (see 3.3.2), and the 
software calculated the degree of spectal overlap. When the same colors were used again in 
another experiment, the compensation controls were applied from a catalogue, and did not 
have to be calculated again. 
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3.3.8 Analysis of results 
For result analysis, FlowJo v. 7.6.5 (TreeStar Inc.) was used. 
 
One of the main tasks was to analyze the CD4 T cell effector functions (cytokine production). 
It is desirable to look at CD4 T cells only, and it is necessary to gate for these cells. Gating of 
live CD4 T cells is illustrated in figure 3.4. First, the main population is chosen based on the 
dotplots of SSC and FSC. From this, SSC against CD3 dotplot is chosen, and the CD3 
positive population is gated for. From a dotplot of CD8 versus CD4, the CD4 positive CD8 
negative cells are gated for (on figure 3.4 CD8 was not stained for, and gating was performed 
using a SSC/CD4 dotplot) and from these, the live CD4 T cells can be further analyzed. 
 
After the CD4 T cells are selected, cytokine production may be analyzed. When all three 
cytokines are pooled using one single cytokine, the analysis is rather straight forward. The 
cytokine channel is chosen as x axis in a dotplot, and SSC may be chosen as the y axis. Proper 
controls are used in determination of gating boundaries, and the positive population is 
detected, and may even be further analyzed, for example for memory differentiation. 
 
When the three cytokines are stained in different channels, analysis is a bit more complicated. 
In a dotplot, analysis is restricted to two characteristics at once, while it is desirable to 
consider all three cytokines simultaneously. To achieve this, a tool in the FlowJo software 
called 'combination gates' is used. Boolean combination gates can be used to create a gate that 
is a combination of any other existing gates, where Boolean operators AND, OR and NOT are 
used. Creating combination gates from IFN-γ+, TNF+ and IL-2+ populations provides new 
gates that show all possible combinations between these three. One single triple positive 
population is created, three double positive, three single positive and one triple negative. 
These calculations and percentages can be exported to Excel to create pie charts representing 
the relative proportions of single, double and triple producers. The importance of this is 
obvious, as triple producers represent the more healthy CD4 T cells that are best suited to 
fight mycobacterial infection (refer section 1.4.3). 
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Figure 3.4: Gating of CD4 positive T cells. The main population is gated for from the SSC and FSC 
dotplots. The CD3 positive population is gated for from the SSC/CD3 dotplots. Dead cells are excluded by 
the gating of the negative population from the live/dead (eBioscience Fixable viability dye e780) channel. 
CD4 positive T cells are identified from the SSC/CD4 dotplots. 
 
3.4 Expansion of mycobacteria-specific T cells 
One experiment was performed using an expanded population of mycobacteria-specific T 
cells from a HIV patient. Expansion of the T cell population greatly increases the proportion 
of specific cells, as specific T cells in culture will divide. 
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For this experiment, isolated PBMCs were diluted in RPMI 10 % A+ to a working 
concentration of 3,5 • 106 cells/mL. Cells were seeded in a 24 well flat bottom plate, 1 mL per 
well. For stimulation, heat-killed M.avium was added at MOI (multiplicity of infection) 5:1. 
 
At day two, 20 U (units) IL-2 was added to the T cells. IL-2 is a potent growth factor for T 
cells and causes T cell proliferation. As T cells encounter their specific antigen presented in a 
MHC context, the cells start dividing. For four to five days the cells divide two to three times 
a day, creating a monoclonal T cell population (as mentioned in 1.4.1). 
 
In parallel, autologous monocyte-derived macrophages (MDM) were generated. PBMCs were 
diluted in RPMI 10 % A+ to a working concentration of 2 • 106 cells/mL and seeded in 96-
well flat bottom plates. 100 μL (0,2 • 106 cells) were added to each well. Cells were incubated 
at 37 °C for 1 hour, just enough time for the monocytes to selectively adhere to the bottom of 
the plate.  
 
Monocytes are the cell type with the greatest affinity for the culture substrate and therefore 
the first to adhere, often already after 30 minutes (155). The rest of the cells were eliminated 
from culture by removing the supernatant and washing the monocytes three times with warm 
HANKS buffer. For the generation of macrophages, monocytes were cultured in RPMI 
medium 30 % A+ serum for nine days in 37 °C. 
 
At day nine, the MDMs were stimulated using heat-killed M.avium and PPD from M.avium 
and M.tuberculosis and co-cultured with the expanded T cells for 16 hours. This induces 
cytokine production in the expanded population of specific T cells. 
 
After stimulation overnight, cells were treated with protein secretion inhibitor and 
extracellular and intracellular staining were performed as described in 3.3.5 and 3.3.6. T cells 
were analyzed for effector functions on a flow cytometer. 
 
3.5 PCR 
PCR is a method used in biological sciences to amplify short pieces of DNA into large 
amounts. Real time PCR, as utilized in this study, is mainly used for quantification of DNA 
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segments. Quantification may be absolute, as in number of copies, or relative, when 
normalizing agents such as housekeeping genes are used. 
 
This study used quantitative real time PCR to determine the relative amounts of cytokine 
mRNA made by PBMCs stimulated with PPD from M.avium and M.tuberculosis and heat-
killed M.avium. Upon such stimulation, signaling cascades (e.g. from PRRs) induce activation 
of transcription factors, a process that leads to the transcription of cytokine genes. This leads 
to accumulation of cytokine specific mRNA inside the cells, these levels can be measured by 
real time PCR after RNA isolation from lysed cells. After 16 hours of stimulation in round 
bottom 48-well plates, plates were centrifuged and the supernatant removed (and used for 
ELISA, see below). The cells were lysed to access the mRNA. To achieve lysis, cells are 
treated with RLT buffer (QIAGEN) containing guanidine-thiocyanate. β-Mercaptoethanol is 
added to degrade RNases. mRNA is then isolated and transcribed to cDNA. This cDNA was 
loaded to a PCR machine that amplifies the DNA strand and quantifies the original amount of 
mRNA present in the sample. 
 
The PCR was performed using probe pairs for three genes: TNF, IFN-β and IL-1β. As 
normalizing agent, the housekeeping gene GAPDH was used. 
 
3.5.1 Assay procedure 
RNA was isolated using the RNeasy Mini Kit (QIAGEN), a kit designed to extract high-
quality RNA from small amounts of animal cells. The process was fully automated using 
QIAcube (QIAGEN). The principle behind the process is the binding of RNA (as samples are 
already lysed) to silica membranes in so-called spin-columns in an environment containing 
ethanol to provide optimal binding conditions. RNA is later eluted in a new tube. A DNase 
digest step was included as a RNA clean-up step to eliminate genomic DNA contamination. 
 
To determine the RNA concentration, a NanoDrop 1000 spectrophotometer (Thermo 
Scientific) was used. This device provides information on both the concentration and the 
quality of the extracted RNA. 
 
RNA need to be converted to complementary DNA (cDNA) before PCR, and the High 
capacity RNA-to-cDNA kit (Applied Biosystems) was utilized. cDNA is produced by 
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enzymes reverse transcriptase and DNA polymerase in the presence of nucleotides. To control 
the temperature, the C1000 thermal cycler (Bio-Rad) was programmed in the following way 
to ensure optimal conditions for cDNA synthesis: 25 ºC for 10 minutes, 37 ºC for 120 
minutes, 85 ºC for 5 minutes and hold at 4 ºC. 
 
As cDNA synthesis is complete, quantitative real-time PCR can be performed. In a reaction 
tube, cDNA is mixed with TaqMan probes for the genes of interest and a mastermix. The 
samples are loaded onto StepOnePlus™ Real-Time PCR System (Applied Biosystems) that 
analyzes the gene expression from the detection of fluorescent light as the TaqMan probes are 
inserted to the DNA strand and later destroyed. 
 
The samples were processed using the quantitative ∆∆CT program at the following settings: 
50ºC for 2 minutes, 95 ºC for 20 seconds and 40 cycles of 95 ºC for 1 second and 60 ºC for 20 
seconds. 
 
3.5.2 Analysis of results 
The software calculates the gene expression of the target sample normalized to the 
endogenous control; the housekeeping gene GAPDH and a calibrator (the unstimulated 
sample). This yields the value relative quantification (RQ). The RQ value is the fold change in 
samples compared to the calibrator. The calibrator gets a value of 1, and all samples are 
compared to this control. 
 
3.6 ELISA 
ELISA is a biochemical assay that detects the presence of a given substance in a sample. The 
substance is often an antigen, but is in this case a cytokine, TNF. This ELISA was performed 
as a 'sandwich' ELISA, meaning an ELISA plate is first coated with an antibody specific for 
the cytokine of interest, before sample is added and the cytokine binds to the antibody. Yet 
another antibody, specific for another epitope on the cytokine is added and binds the cytokine. 
The second and so-called detection antibody is later conjugated via streptavidin to an enzyme 
(HRP) that causes a color change in the wells upon addition of enzyme substrate. This color 
change is measured optically and represents the amount of cytokine present in the sample. 
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Upon stimulation, the antigen-specific cells in the cell population will start producing 
cytokines and release them into the surroundings. ELISA cytokine analysis was performed 
from the cell culture supernatant using the samples where mRNA was analyzed by real time 
PCR (see 3.5). 
 
The ELISA is performed using Human TNF-α DuoSet kit provided by R&D Systems. The 
principle behind the method is to make a standard curve using known concentrations of the 
cytokine of interest. From this standard curve it is possible to determine the concentrations of 
TNF in the unknown samples. 
 
Samples were analyzed both undiluted and in a 1:10 dilution. The stimulation was performed 
in duplicates, and for the ELISA, duplicates were analyzed for every sample, meaning each 
biological replicate was analyzed four times. Unstimulated cells and PMA-stimulated cells 
were included as negative and positive controls, respectively. Each known concentration in 
the standard curve was analyzed in triplicates. 
 
3.6.1 Assay procedure 
The assay was performed according to the user manual provided by R&D Systems. In brief, a 
flat bottom 96-well ELISA half area plate (NUNC) was coated with mouse anti-human TNF-
α and left overnight to have the capture antibody bind to the plate. Washing buffer is used to 
remove unbound antibody. The ELISA wash buffer contains tween 20, a detergent that helps 
prevent unspecific antibody binding. The plate is later blocked using a solution containing 
bovine serum albumin (BSA). BSA will bind to sites in the well not already bound by capture 
antibody to prevent unspecific binding later on. 
 
Standard solutions and samples are added to individual wells and are left to react so TNF-α in 
samples are able to bind to the capture antibody in the well. After washing, the second 
antibody is distributed to the wells and bind to a second epitope on the cytokines in the 
sample. As a streptavidin-HRP (horseradish peroxidase) conjugate is later added to the 
samples, streptavidin binds to multiple sites on the detection antibody. The last assay step is 
the addition of a mixed substrate solution, a substance that reacts in the presence of HRP 
enzyme to produce a color change. Stop solution N2SO4 inhibits the enzyme catalyzed 
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reaction, and the optical density (OD) can be measured in a spectrophotometer at wavelength 
450 nm. 
 
3.6.2 Determination of sample concentrations 
For OD measurement and data analysis, the software Bio-Rad Microplate Manager was used. 
From the measured OD (after a blank was subtracted), a standard curve was constructed from 
plotting OD against known concentrations. The concentration range went from 15,6 pg/mL to 
1000 pg/mL. To customize a regression for the data set, a so-called «4-Parameters Fit» was 
used. This regression represents y as follows in equation (3.1). 
 y = (A-D)/(1+(X+C)^B)+D        (3.1) 
where A, B, C and D are fixed constants. 
 
The measured OD for the unknown samples are inserted as y values in (3.1), and the TNF-α 
concentration in pg/mL for the different unknown samples can be calculated by solving for X. 
 
3.7 Ethical issues 
Blood from HIV positive patients and healthy donors was used in this study. All patients gave 
their written and informed consent to participate in research related to their HIV disease. The 
study was approved by the Regional Ethics Committee (ID: 2012/153/REK midt). 
 
Handling of HIV blood was performed under BL3 conditions, and all samples and results 
were anonymized. 
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4. Results 
The project was divided in two parts. The first part consisted of optimization of methods to 
best preserve peripheral blood mononuclear cells (PBMCs) and analyze their effector 
functions. For this purpose, blood from healthy donors was utilized. 
 
The second part was the patient study that took use of blood from HIV positive patients and 
healthy controls. 
 
The first part of the results section describes what was discovered during the analysis, and 
method optimization in the preliminary study. This includes flow cytometry and tests to 
determine whether analysis of HIV samples may be performed using frozen specimen, how to 
distribute protein secretion inhibitor to the cells, dosage controls of cells per well and 
intracellular stain, the effect of short-term storage on stained and fixed cells. These optimized 
protocols were then applied in a patient study focusing on cytokine production and memory 
differentiation phenotype in HIV patients. At last, results from experiments using PCR and 
ELISA to study total cytokine production will be presented. 
4.1 Preliminary studies 
4.1.1 Influence of cryopreservation on cytokine production from CD4+ T 
cells 
For a study using patient samples, long-term storage of samples may be of great importance. 
Few patient samples are available each day or week, and for reproducibility and comparability 
reasons it may be beneficial to analyze several samples simultaneously. It was therefore 
investigated if PBMC quality is impaired when cells are kept at sub-zero temperatures. 
 
White blood cells were isolated from healthy donors' heparinized blood using ficoll-hypaque 
density gradient (see 3.2.1). After blood cell isolation, 3-7.5 • 106 PBMCs were transferred to 
NUNC (Nalgene) cryotubes containing a DMSO-based freezing medium and duplicate 
samples were stored in liquid nitrogen or a -80 °C freezer (see 3.2.2). 
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Cells were thawed after approximately three months, and their viability examined using 
Countess automated cell counter (Invitrogen). Cryopreservation did not seem to have any 
effect on the viability prior to stimulation, as it remained stable at around 90-95 % for both 
fresh and frozen specimen (data not shown). There was no significant difference between 
cryopreservation in liquid nitrogen or -80 °C. 
 
Effector functions were compared between fresh PBMCs and frozen samples from the same 
donor, preferably stored both in liquid nitrogen and in -80 °C. Each sample was stimulated 
(described in 3.2.3) and stained for identification and cytokine production (3.3.5/3.3.6). All 
three cytokines (IFN-γ, TNF and IL-2) were stained using the same fluorochrome (PE). 
Analysis was performed using flow cytometry (see section 3.3). 
 
Results for one representative donor are shown in figure 4.1 below. Other donors were 
analyzed with similar outcomes. The figure shows the percentage of live CD3+CD4+ T cells 
that can produce any of the three cytokines (TNF, IFN-γ or IL-2) in response to stimulation 
with mycobacterial antigens. PBMCs have been cryopreserved for three months, and cells are 
gated using isotype controls. Gating strategy for detection of cytokine-producing live CD4+ T 
cells is shown in figure 4.1 A. The cytokine-positive population from the last dotplot 
represents the red column corresponding to M.avium PPD in figure 4.1 B. Surface markers 
seem not to be influenced by cryopreservation (data not shown). Stimulation with the 
aforementioned agents gives rise to mycobacteria-specific CD4+ T cells that are able to 
produce cytokines above background signal. Fresh cells provide the strongest signal and show 
the largest proportion of mycobacteria-specific CD4+ T cells (figure 4.1 B). 
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Figure 4.1: Cytokine production from fresh or cryopreserved CD3+CD4+ T cells in response to 
stimulation with mycobacterial antigens. A. Gating strategy. PBMCs from the same donor were 
stimulated overnight before adding protein secretion inhibitor. Cells were stained with CD3, CD4 and 
CD8 on the surface, and a live/dead staining procedure based on dye exclusion was included. After 
fixation and permeabilization, cells were intracellularly stained for three effector cytokines (TNF, IFN-γ 
and IL-2) in the same channel (using PE fluorochrome). Cells were gated for live CD3+CD4+CD8- T cells. 
B. Analysis of cytokine production (cytokine-positive populations from figure A) as shown by the 
percentage of CD4+ T cells that produce any if the three effector cytokines. Fresh cells are compared to 
cells that have been stored in liquid nitrogen and -80 °C for three months. Unstimulated cells are included 
as controls. 
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Cells that have been frozen and thawed showed the same pattern as the fresh cells although a 
decrease in total cytokine production was seen. The tendency was found for both storage 
methods, but is more profound for PBMCs stored at -80 °C compared to liquid nitrogen. 
Results indicate that PBMCs can be stored in liquid nitrogen and still retain most of their 
effector functions and yield results that are comparable to fresh cells. Long-term storage of 
PBMCs in liquid nitrogen therefore seems to be possible for analyzing cytokine production 
from CD4+ T cells. However, as the proportion of specific cells is low after stimulation 
overnight, decrease in cytokine production may be significant and using fresh cells should be 
considered. Fresh PBMCs was used in this project, but PBMCs from HIV patients were stored 
in liquid nitrogen as a back-up for repeating experiments.  
 
Difference between cells that were kept in liquid nitrogen and those kept in -80 °C is also 
seen when taking viability post stimulation (using eBioscience Fixable Viability Dye) in to 
consideration. For cells stored in a regular -80 °C freeze container, viability drops compared 
to fresh cells, whereas cells that have been stored in colder conditions in a liquid nitrogen 
tank, show the same viability as fresh cells (data not shown). 
4.1.2 Inhibition of secretion of mycobacteria-specific effector cytokines 
produced by CD4+ T cells 
This project seeks to analyze the cytokine production from CD4+ T cells which normally are 
secreted from these cells and released to the extracellular space. Cytokines need therefore be 
accumulated within the cells, and this is achieved by treatment with a protein transport 
inhibitor cocktail (eBioscience 500x) that inhibits transport pathways out of the cell. 
 
Manufacturer (eBioscience) recommends leaving the protein transport inhibitor on cells for 
five to 18 hours. Within the research group, regular practice has been to stimulate PBMCs for 
16 hours, before adding protein transport inhibitor and incubating four new hours. However, 
waiting 16 hours from stimulation to inhibition of secretion may lead to loss of some of the 
early produced cytokines, as they are known to possess varying kinetics (83)(89). To 
investigate this and conclude on what time frame is the ideal to achieve best possible signal in 
flow cytometric assays, two different approaches were tested: The one just described, and one 
where the protein transport inhibitor was added one hour after stimulating agents and left on 
cells for 16 hours. 
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Cells were stimulated and stained as described in 3.2.3 and 3.3.5/3.3.6, respectively. 
 
 
 
Figure 4.2: Optimal time interval for inhibition of cytokine-secretion to detect IFN-γ production in 
mycobacteria-specific T cells. A. Cells were stimulated using heat-killed M.avium and transport inhibitor 
cocktail was added one hour post stimulation and left on cells for 16 hours. B. Cells were stimulated with 
heat-killed M.avium overnight (~ 16 hours) and transport inhibitor cocktail was distributed to the cells for 
another four hours. For both methods, cells were stained for CD3, CD4 and CD8, fixed, permeabilized 
and stained for effector cytokines in three different channels. Cells were gated CD3+CD4+CD8- and 
analyzed for production of IFN-γ (x axis). Unstimulated controls are shown on the left, HK M.avium -
stimulated cells on the right. 
 
Results show marked differences between the two methods. When protein transport inhibitor 
is added just one hour after stimulation, cells show low to moderate production of IFN-γ and 
IL-2, and moderate to high production of TNF. When added 16 hours after stimulation, large 
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amounts of IFN-γ are produced, while TNF and IL-2 levels decline compared to the first 
method. Figure 4.2 shows how the two different methods influence the production of IFN-γ. 
No cytokine production above background signal is detected when transport inhibitor is added 
one hour post stimulation, whereas large amounts are produced after 16 hours. On the basis of 
these results, it was decided to add protein transport inhibitor after 16 hours of stimulation and 
for another four hours. 
4.1.3 Optimal cell numbers for the mycobacteria-specific T cell stimulation 
assay 
Experiments were carried out to optimize the flow cytometric assay in order to determine 
what conditions are the best possible when investigating T cell effector functions. As the 
number of PBMCs are often scarce, especially when receiving blood from HIV patients, it is 
necessary to use the least number of cells possible while still being able to execute the 
experiments in a satisfactory manner. To test this, PBMCs were seeded in the range from 0,2 • 
10
6
 to 10
6
 per well. During flow cytometry, 50 000 cells were acquired. Results are shown in 
figure 4.3. 
 
The figure shows no tendency for differences between the different dosages and the small 
variation can probably be attributed well-to-well variations. This means that the whole range 
of cell numbers may be utilized. However, obtaining the desired number of at least 50 000 
cells per flow-analysis may be difficult if initial PBMC concentration is too low. As the 
proportion of specific T cells is small, increasing the number of events to record from 50 000 
to 100 000 in the flow cytometer may be beneficial, which provides even more stringent 
requirements for initial cell concentration. Based on this, PBMCs were normally seeded in a 
concentration of 0,5 • 106 cells per well. 
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Figure 4.3: Analysis of effect of different numbers of cells per flow cytometric sample. Cells were 
stimulated with heat-killed M.avium overnight. On the surface they were stained for CD3, CD4 and CD8. 
Cells were then fixed and permeabilized and stained intracellularly for the three effector cytokines (TNF, 
IFN-γ and IL-2). Live cells were gated CD3+CD4+CD8-, analysis of production of IFN-γ (y axis) and TNF 
(x axis) are shown. Cell number per well varied and is indicated on the figure. 
 
4.1.4 Antibody titration for optimal fluorescence staining of effector 
cytokines 
The dosage of fluorescent dye for intracellular staining was also tested. Manufacturers often 
recommend using a specific volume of dye per test which should give sufficient staining for 
example for 10 • 106 cells. However, it is recommended that the optimal concentration of each 
antibody should be tested for each application. Finding the correct amount of fluorescent dye 
is one of the most important issues in immunophenotyping, as deviations from the ideal 
volume may affect the results. Too much antibody will increase unspecific binding and 
thereby reduce the signal-to-noise ratio. If the amount is not high enough, fluorescent staining 
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will be incomplete, a critical problem for an assay like this (170). As we only have low cell 
number (a maximum of 0,5 • 106 cells per well) and low numbers of cytokine-producing cells 
(usually less than 1 %), it is important to specifically detect these cells with a good signal and 
as little background as possible at the same time. It was therefore chosen to use bright 
fluorochromes with a high staining index for staining of effector cytokines (refer section 
3.3.4). 
 
In addition, experiments were performed where the amount of fluorescence-labeled effector 
cytokine antibodies was titrated to find the optimal concentration for the assay. 
 
PBMCs were stimulated (3.2.3) using heat-killed M.avium and stained for CD3, CD4 and 
CD8 for identification. For the intracellular stain, a five-point range from 0,2 to 5 μL (0,4 - 10 
μg/mL) dye per test was used, the three cytokines (TNF, IFN-γ and IL-2) were all tested 
simultaneously. Measured fluorescent signal for cytokines TNF (x axis) and IFN-γ (y axis) 
are shown in figure 4.4. Signal increases as amount of dye is increased. For simplicity (using 
the same volume of dye for the extracellular and intracellular staining) and cost efficiency, it 
was chosen to use 2 μg/mL for future analysis. 
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Figure 4.4: Antibody titration for staining of intracellular cytokines. Cells are stimulated overnight using 
heat-killed M.avium and stained for extracellular and intracellular markers. Live CD3+CD4+ cells are 
shown. TNF is shown on the x axis, IFN-γ on the y axis. Fluorochrome concentration varied and is 
indicated on the figure. 
 
4.1.5 Influence of short-term storage of fixed and stained cells before 
analysis of effector cytokine production by flow cytometry 
The day after stimulation, cells are extracellularly stained for surface markers and fixed in a 
paraformaldehyde (PFA) solution. PFA crosslinks the proteins and makes it possible to store 
the cells in 12 × 75 mm polystyrene tubes at 4 °C without any damage to intracellular 
structures. Intracellular staining and flow cytometry is usually performed the next day. 
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Analyzing the samples before their stability is compromised is essential, as fluorochromes 
may bleach in light or degrade (for example for tandem dyes), thus influencing the results. 
 
To examine the effect of short-term storage of stained cells on the end result of flow 
cytometry, 12 × 75 mm polystyrene tubes («flow tubes») were analyzed on day zero after 
finishing intracellular staining procedure and flow cytometry was repeated on the same tubes 
on day five (after storage at 4 °C). Results are shown in figure 4.5 for one representative tube. 
The results indicate that storage of stained and fixed cells for at least five days have little, if 
any, effect on the results. All samples were analyzed on day five, yielding the same result as 
below, meaning with no significant change in signal from day zero to day five. Despite this, 
samples were normally analyzed on the same day as intracellular staining was performed. 
 
 
Figure 4.5: Effect of storage of stained and fixed cells on detection of effector functions. PBMCs are 
stimulated overnight using heat-killed M.avium. Cells are then stained extracellularly, fixed, 
permeabilized and stained intracellularly. Cells are live and CD3+CD4+, and cytokine production is 
represented by TNF (x axis) and IL-2 (y axis). Left is shown flow cytometric analysis at day zero, right is 
flow cytometric analysis performed on the same tube at day five, after storage at 4 °C. 
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4.1.6 Multicolor flow cytometry protocol for phenotyping of effector 
cytokine production and memory status of CD4+ T cells 
The previous sections (4.1.1 to 4.1.5) describe how the method for analysis of mycobacteria-
specific CD4+ Th1 cells using flow cytometry was optimized. This method was then used for 
analyzing cytokine polyfunctionality and memory differentiation in HIV patients and healthy 
donors. 
 
It was found that fresh cells are the preferred choice for studying mycobacteria-specific 
cytokine production, due to a decrease in the percentage of specific cells after 
cryopreservation. However, cells stored in liquid nitrogen for up to three months are possible 
options if necessary. For this study, fresh cells were normally the choice, and all PBMCs from 
HIV patient samples were analyzed fresh. PBMCs from HIV patients were also stored in 
liquid nitrogen, meaning they can be analyzed at a later stage of the research project. 
 
The distribution of protein secretion inhibitor was found to influence the cytokine production, 
as cytokines inhibit varying kinetics. TNF seems to accumulate early after stimulation, and 
yields best results in the subsequent flow cytometric assay if protein transport inhibitor is 
distributed to the cells one hour post stimulation, as TNF levels seem to decrease relatively 
early. IFN-γ is secreted at a later stage, and for this cytokine, it is preferred to wait 16 hours 
after stimulation before adding secretion inhibitor, leaving it for four hours. Leaving the 
protein transport inhibitor on the cells for too long may influence the cells in a negative 
manner and should thus be avoided. It was decided to always wait for 16 hours after 
stimulation before adding protein transport inhibitor. Deviations from the protocol should be 
avoided for as long as the study is ongoing. 
 
It was also decided on always seeding cells at a concentration of 0,5 • 106 cells per well, as 
this amount was necessary to obtain the desired 50 000 – 100 000 events per flow cytometric 
analysis. Both extracellular and intracellular antibodies were distributed to the cells at a 
concentration of 2 μg/mL. 
 
Based on this, it was decided on a protocol where PBMCs were isolated (3.2.1) and seeded 
fresh in flat bottom 96-well plates (12-13 wells per donor). Cells were stimulated (3.2.3) using 
three mycobacterial antigens; M.avium PPD, M.tuberculosis PPD and heat-killed M.avium. 
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All stimulating agents were distributed in duplicates, and in addition to cells stimulated with 
mycobacterial antigens, two wells were unstimulated as negative controls, and two wells were 
stimulated using cell stimulation cocktail for positive control. Some extra wells were 
stimulated with heat-killed M.avium for controls. Cells were then incubated in 37 °C 
overnight to a total of approximately 16 hours, before adding protein transport inhibitor, 
leaving this on for another four hours. 
 
Half the panel was stained extracellularly and intracellularly (3.3.5/3.3.6) for the purpose of 
investigating the mycobacteria-specific CD4+ T cell cytokine production and 
polyfunctionality. This means the three cytokines IFN-γ, TNF and IL-2 were stained using 
three different, bright fluorochromes. In addition, identification markers (CD3, CD4 and 
CD8), a live/dead stain and some memory markers were included. The other half was stained 
for the purpose of examining memory differentiation in CD4+ T cells and mycobacteria-
specific CD4+ T cells. To be able to stain as many surface memory markers as possible, the 
three cytokines were stained using the same fluorochrome. Identification markers (CD3, CD4 
and CD8), live/dead stain and six memory markers (CD27, CD28, CD45RO, CCR7, PD-1, 
HLA-DR) were also included. For some donors, an additional tube was stained using CD57 
instead of CCR7 (the two antibodies occupied the same channel). This means 11 of the 16 
possible filter combinations on the flow cytometer was used during analysis. Controls always 
included isotype controls for all memory markers and all cytokines. When compensation was 
required, one tube was prepared for all fluorochromes, with one drop of compensation beads 
and 1 μL of the fluorochrome of interest. 
 
Bright and stable colors were chosen for the effector cytokines and memory markers, less 
bright colors for the major populations CD3, CD4 and CD8 (refer 3.3.4). Use of unstable 
tandem dyes was limited. 
 
Figure 4.6 shows an example of how samples were analyzed using the final protocol. FSC, 
SSC and identification markers CD3, CD4 and CD8 are used to identify the CD4+ T cell 
population of interest, and a live/dead stain is included to exclude dead cells from further 
analysis. From the live population, cytokine production and expression of surface memory 
markers may be identified. 
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Figure 4.6: Gating strategy for patient study. PBMCs from healthy donors or HIV patients were 
stimulated overnight using M.avium PPD, M.tuberculosis PPD as well as heat-killed M.avium before 
protein secretion inhibitor was added for four hours. Cells were stained with CD3, CD4 and CD8 on the 
surface for identification, as well as some memory markers. A live/dead staining procedure based on dye 
exclusion was included. After fixation and permeabilization, cells were intracellularly stained for effector 
cytokines. Cells were gated for live CD3+CD4+CD8- T cells, before marker of interest (cytokine or 
memory marker) was investigated. 
4.2 Patient study 
 
4.2.1 Mycobacteria-specific cytokine production by CD4+ T cells in healthy 
individuals and HIV patients 
To determine to what extent healthy individuals can mount a response towards mycobacterial 
antigens, T cell effector functions were examined using cytokines TNF, IFN-γ and IL-2 as 
markers for T cell specificity. These cytokines are main targets in assays investigating 
infections caused by mycobacteria (refer section 1.4.3). Polyfunctional T cells (PFT) are able 
to produce several of these effector cytokines simultaneously and are considered particularly 
important in controlling tuberculosis infection (92)(93)(97). Not much is known about their 
importance in M.avium infection, but it was desirable to analyze polyfunctionality of CD4+ 
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Th1 responses from healthy individuals and HIV patients in response to antigens from 
M.tuberculosis as well as from M.avium. 
 
Effector cytokine production from healthy donors (4.2.1.1 and 4.2.1.2) as well as HIV patients 
(4.2.1.3) were analyzed with the optimized protocol described in section 3.2 and 3.3 and in 
the first part of the results (final protocol in 4.1.6). Bright fluorochromes with high staining 
index were used to detect the effector cytokines IFN-γ, TNF and IL-2 from different channels. 
Colors used were PE, BV421 and APC, respectively. This enables to determine the relative 
proportions of single producers (producing any of the three cytokines), double producers (any 
two cytokines) or triple producers (all three cytokines). To determine the relative proportions, 
Boolean gating was used (section 3.3.8). 
 
For information about the HIV patients that were recruited to the study, see section 3.1. 
 
4.2.1.1 Mycobacteria-specific CD4+ T cell effector cytokine production in 
healthy individuals 
Fresh PBMCs from healthy individuals were isolated (section 3.2.1), stimulated (section 
3.2.3) and stained for T cell effector cytokine production (3.3.5/3.3.6). Three different 
mycobacterial antigens were tested; M.avium PPD, M.tuberculosis PPD and heat-killed 
M.avium, as well as unstimulated negative controls and PMA-stimulated positive controls. 
Results from some donors were rejected, as their handling procedures deviated from the final 
protocol described in 4.1.6. Samples were also eliminated if the signal-to-noise ratio was low 
or if the positive control did not work. A positive response was defined as twice the signal 
from the unstimulated negative controls. For the final result, four healthy BCG-vaccinated 
donors were included, men and women ranging from 30 to 55 years old. 
 
All healthy donors responded to mycobacterial antigens. 
 
Effector cytokine production of CD4+ T cells in response to overnight stimulation with 
mycobacterial antigens from four different healthy donors is shown in figure 4.7. Relatively 
large donor variability was detected, as can be seen from figure 4.7 A, where percentages of 
total mycobacteria-specific T cells (producing one, two or three cytokines) are plotted for 
stimulation with M.avium PPD, M.tuberculosis PPD and heat-killed M.avium. Generally, 
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responses ranged from 0,2 to 0.7 % for overnight stimulation with mycobacterial antigens. All 
donors have been vaccinated with Bacille Calmette-Guérin (BCG), a vaccine meant to 
provide long-term protective immunity against tuberculosis. Although earlier believed to 
greatly decrease the risk of tuberculosis (171), the vaccine was later found to be ineffective 
against adult pulmonary disease (172). 
 
The degree of polyfunctionality also varies among the different donors, as seen in figure 4.7 
B, indicating different degrees of polyfunctionality for the donors against M.avium PPD. For 
the majority of donors, single producers secreting either TNF, IFN-γ or IL-2 are predominant 
(34-93 %). For one of the donors, the majority of the mycobacteria-specific cells was found to 
be triple producers. The three donors with single producers as the predominant cells 
correspond to the three highest percentages of total cytokine-producing cells (4.7 A). IFN-γ is 
the predominant cytokine among the monofunctional cells, with TNF second. IL-2 is almost 
absent among monofunctional cells (data not shown). 
 
When results from all donors are combined, monofunctional T cells are still predominant, 
accounting for approximately two thirds of all cytokine-producing cells (fig. 4.7 C). The rest 
of the cells are divided almost equally between double producers and triple producers. Among 
the double producers, IFN-γ+TNF+ cells are most predominant. 
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Figure 4.7: CD4+ T cell cytokine production from healthy individuals in response to antigens from 
M.avium and M.tuberculosis. PBMCs are stimulated overnight with three different stimulating agents 
originating from mycobacteria. Cells are stained with CD3, CD4 and CD8 on the surface, and a live/dead 
staining procedure based on dye exclusion is included. After fixation and permeabilization, cells were 
intracellularly stained for three effector cytokines (TNF, IFN-γ and IL-2) in three different channels 
(eFluor450, PE and APC, respectively). Cells were gated for CD3+CD4+CD8- T cells and cytokine 
production analyzed. T cell response of four different healthy and BCG-vaccinated donors was analyzed. 
A. Percentage of total mycobacteria-specific T cells producing one, two or three cytokines in response to 
PPD from M.avium and M.tuberculosis as well as heat-killed M.avium. B. The total effector cytokine 
response of the four healthy donors towards M.avium PPD from figure A was split into cells producing 
one, two or three cytokines to analyze polyfunctionality. Blue zones represent single producers, red zones 
double producers and green zones triple producers. C. Cytokine response results of all four donors from 
A were combined and polyfunctionality analyzed. The average of single, double and triple cytokine 
production from the four donors towards M.avium PPD, M.tuberculosis PPD and heat-killed M.avium is 
shown. 
 
 
Results 
___________________________________________________________________________ 
69 
 
4.2.1.2 Mycobacteria-specific CD4+ T cell effector cytokine production in a non-
BCG vaccinated healthy donor 
One of the healthy donors recruited to the study was not BCG vaccinated. Following the exact 
same experiment set-up as described for the rest of the healthy donors, her PBMCs were 
analyzed, and results can be seen in figure 4.8. The number of specific T cells were low 
(ranging from 0.15 to 0.22 for the three different stimulating agents), quite below the mean 
for the four BCG vaccinated donors. However, there was a clear population of mycobacteria-
specific CD4+ T cells found in response to stimulation with all three mycobacterial antigens 
that was not found for the unstimulated control (example shown in figure 4.8 A for heat-killed 
M.avium). The polyfunctionality resembles that of the other donors, although the proportion 
of single producers is a bit higher, ranging from 74-80 % against the three antigens (figure 4.8 
B). 
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Figure 4.8: CD4+ T cell cytokine production from a non-BCG vaccinated healthy donor in response to 
antigens from M.avium and M.tuberculosis. A. Response from donor, unstimulated (left) and towards 
heat-killed M.avium (right), represented by production of IFN-γ (y axis) and TNF (x axis). B. 
Polyfunctionality of the non-BCG vaccinated donor in response to PPD from M.avium and M.tuberculosis 
as well as heat-killed M.avium The average of single, double and triple cytokine production from the four 
donors towards M.avium PPD, M.tuberculosis PPD and heat-killed M.avium is shown. Blue zones 
represent single producers, red zones double producers and green zones triple producers. 
 
4.2.1.3 Mycobacteria-specific CD4+ T cell effector cytokine production in HIV 
patients 
Cytokine production in HIV patients was also analyzed. However, obtaining satisfying results 
was a challenge. First and foremost, patient sampling and approval of the study by the 
regional ethics committee delayed the process. It was therefore possible to recruit only seven 
HIV patients to the study. Some samples were rejected due to very low CD4 count, making 
the subsequent analysis of cytokine production in mycobacteria-specific CD4+ T cells almost 
impossible. For other samples, there was unfortunately a problem of no cytokine production 
above background signal. This could be due to for example a problem with one of the cell 
culture reagents such as the medium or serum, as the cells otherwise looked healthy and 
showed no abnormal results from analysis of surface markers (4.2.2).  Therefore it could also 
be possible that these HIV patients were non-responders without detectable numbers of 
mycobacteria-specific CD4+ T cells. It could in this study not be distinguished if the patients 
did not respond or if the negative results were due to a problem in cell culture. But as aliquots 
of PBMCs from patient samples were stored in liquid nitrogen, the analysis can be repeated as 
analysis from cells cryopreserved in liquid nitrogen was found to result in comparable results 
as from fresh cells (4.1.1). The re-analysis with cryopreserved cells was not performed by the 
end of this study, but it is recommended that this is done in the near future. After excluding all 
samples with very low CD4 count and doubtful experiments, samples from two donors could 
be analyzed for mycobacteria-specific CD4+ T cell frequency and polyfunctionality, and the 
results can be seen in figure 4.9. One of the donors show a moderate mean response towards 
the antigens, the other show relatively little response (figure 4.9 A). It is obvious from the 
results that a great majority of mycobacteria-specific cells are single producers (figure 4.9 B). 
Triple producers are almost absent among these two HIV patients. IFN-γ is the most 
predominant cytokine among the single producers, with TNF second. 
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Figure 4.9 Polyfunctionality of HIV patients in response to PPD from M.avium and M.tuberculosis as well 
as heat-killed M.avium A. Frequencies of mycobacteria-specific CD4+ T cells towards the different 
antigens in the two HIV patients, given in percentage of CD3+CD4+ T cells. B. The average of single, 
double and triple cytokine production from the four donors towards M.avium PPD, M.tuberculosis PPD 
and heat-killed M.avium is shown. Blue zones represent single producers, red zones double producers and 
green zones triple producers. 
 
4.2.2 CD4+ T cell memory status 
T cell memory phenotype reveals information about the T cell population status. Memory 
cells are long-lived and small populations that are able to exert a rapid response towards 
repeated infections with the same infectious agents (secondary response). The memory 
phenotype is hard to characterize, as no set of markers definitely defines them. They change 
continuously and lose and gain expression of a wide range of markers throughout their life 
span (see section 1.4.4). Additionally, not much is known about the T cell differentiation in 
HIV patients compared to healthy individuals. 
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This project aimed at revealing information about T cell memory phenotype in healthy 
individuals and to compare to that of HIV patients. Seven surface memory markers (CD27, 
CD28, CD45RO, CD57, HLA-DR, PD-1 and CCR7) in addition to T cell identification 
markers (CD3, CD4, CD8) and effector cytokine staining (where all three effector cytokines 
IFN-γ, TNF and IL-2 were stained using the same fluorochrome) were analyzed using flow 
cytometry (see also 4.1.6). 
 
4.2.2.1 CD4+ T cell memory phenotype in healthy individuals 
The first experiment analyzed memory phenotype in healthy individuals. PBMCs were 
stimulated overnight and stained for identification markers and memory markers 
extracellularly, as well as cytokine production (all three cytokines were stained in the PE 
channel). All CD4+ T cells were analyzed, as well as specific cells only (cells producing any 
of the three cytokines in response to stimuli). Results are presented in figure 4.10. Expression 
of CD27 and CCR7 decrease in the specific cells compared to the whole CD4+ T cell 
population, whereas expression of CD45RO, HLA-DR and PD-1 increase (figure 4.10 A). 
There was no significant difference in expression between the different stimulating agents 
(data not shown). Two parameters (CD27 and CCR7) were analyzed in greater detail. These 
markers have been used to describe different T cell memory populations (58)(119)(85)(138). 
Using Boolean gating, their simultaneous expression was elucidated in all CD4 cells and 
specific cells (Figure 4.10 B). It can be seen from the figure that the majority of all CD4 cells 
are CD27+CCR7+, but that CD27-CCR7- cells dominate among the specific population. 
CD27-CCR7+ phenotype is absent from both populations. In addition to analysis of the CD4+ 
T cell memory phenotype, the CD8+ T cell population was also investigated (figure 4.10 C). 
This population shows the same trends as the CD4+ T cell population when first considering 
the CD8+ T cell population as a whole, before looking only at the mycobacteria-specific 
CD8+ T cells, but there are differences in expression of some of the markers between the 
CD4+ and CD8+ T cell populations. Results in 4.10 are from one representative donor.  
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Figure 4.10: CD4+ T cell memory differentiation in one healthy donor. A. Shift in CD4+ T cell memory 
phenotype from the entire CD4+ T cell population to mycobacteria-specific CD4+ T cells only. The x axis 
shows five different memory markers, and the y axis shows their expression in the two different CD4+ T 
cell populations. B. Diagram showing the simultaneous expression of memory markers CD27 and CCR7 
in all CD4+ T cells and mycobacteria-specific CD4+ T cells only. Circles represent all CD4+ T cells, 
whereas squares represent mycobacteria-specific CD4+ T cells. C. Shift in CD8+ T cell memory phenotype 
from the entire CD8+ T cell population to mycobacteria-specific CD8+ T cells only. 
 
4.2.2.2 CD4+ T cell memory phenotype in HIV patients 
To investigate differences in memory phenotype among healthy controls and HIV patients, 
PBMCs from HIV patients were characterized as described for healthy donors (4.2.2.1). 
PBMCs from HIV positive patients were stimulated overnight and stained for identification 
markers and memory markers extracellularly, as well as cytokine production. Due to a low 
number of HIV patients showing reliable results for cytokine production, and the low total 
number of specific CD4+ T cells among them, the memory characterization among the 
specific cells is difficult. Therefore, it was first looked at the CD4+ T cell population as a 
whole, and figure 4.11 shows the difference between healthy individuals and HIV patients 
when all CD4+ T cells are considered. A representation of the difference in CD4+ expression 
among the healthy individuals and HIV patients are included in figure 4.11 A. Healthy 
individuals showed a greater expression of CD4+ T cells among the CD3+ population, but the 
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differences are not that big. For markers CD27, CD45RO and CCR7, there is not much 
difference between healthy controls and HIV patients. However, HLA-DR and PD-1 seem to 
have an increased expression in HIV patients as compared to healthy individuals (figure 4.11 
B). Results are based on analysis of three healthy individuals and five HIV patients. 
 
 
Figure 4.11: CD4+ T cell memory differentiation in healthy individuals compared to HIV patients when 
all CD4+ T cells are considered. A. Expression of CD4+ T cells in the CD3+ population of healthy 
individuals and HIV patients. Results plotted together with bars indicating the standard deviation (SD). 
B. Differences in the expression of five memory markers (x axis) in the entire CD4+ T cell population 
among healthy individuals and HIV patients. Results plotted together with bars indicating the standard 
deviation (SD). 
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Results from the analysis of all CD4+ T cells compared to specific cells only (cells producing 
any of the three cytokines in response to stimuli) are presented in figure 4.12. It was earlier 
stated that the analysis of cytokine production in some of the HIV patients was difficult (see 
4.2.1.3). This also proposes a problem when analyzing memory differentiation in 
mycobacteria-specific CD4 T cells. Distinguishing between cytokine-producing negative and 
positive populations is sometimes ambiguous despite the use of appropriate controls. This 
should be kept in mind when studying the results. Results in figure 4.12 are from two HIV 
patients. 
 
For many of the markers, if not all, there is no great increase or increase from all CD4+ T 
cells to specific cells only (figure 4.12 A). The trend for all of the markers, however, follows 
that of the healthy controls, except HLA-DR, being more expressed in the whole CD4+ T cell 
population than the specific population for the HIV patients. 
 
When analyzing the joint expression of CD27 and CCR7 (figure 4.12 B), the trend for the 
whole CD4+ T cell population resembles the results from the healthy controls. For the 
specific cells, deviations can be seen. The majority (almost 50 %) of the cytokine-producing 
cells express both CD27 and CCR7 memory markers. Few (around 15 %) are double negative 
for these markers. For the HIV patient samples, there seem to exist a CD27-CCR7+ 
population.  
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Figure 4.12: CD4+ T cell memory differentiation in HIV patients. A. Shift in CD4+ T cell memory 
phenotype from the entire CD4+ T cell population to mycobacteria-specific CD4+ T cells only. The x axis 
shows five different memory markers, and the y axis shows their expression in the two different CD4+ T 
cell populations. Results plotted together with bars indicating the standard deviation (SD). B. Diagram 
showing the simultaneous expression of memory markers CD27 and CCR7 in all CD4+ T cells and 
mycobacteria-specific CD4+ T cells only. Circles represent all CD4+ T cells, whereas squares represent 
mycobacteria-specific CD4+ T cells. 
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4.2.3 Expansion of mycobacteria-specific CD4+ T cells and co-culture with 
MDMs for effector cytokine production 
When T cell population is expanded, specific cells proliferate, and this will increase the 
proportion of mycobacteria-specific T cells in culture compared to staining after just 16 hours 
of stimulation. As the proportion of specific cells after overnight stimulation is low, usually 
below 1 %, T cell expansion can make the cytokine-producing population easier to detect and 
investigate. An experiment was conducted to examine what happens if HIV patient samples 
are expanded, as that had not earlier been done in the research group. PBMCs were stimulated 
using heat-killed M.avium to activate mycobacteria-specific T cells. Simultaneously, 
autologous monocyte-derived macrophages (MDMs) were cultured. T cells and stimulated 
MDMs were co-cultured after ~ 10 days and for ~ 16 hours (refer section 3.4). It should be 
noted that the expanding population of T cells were handled in parallel with samples that did 
not seem to produce any cytokines above background when running flow cytometry after just 
16 hours of stimulation (refer section 4.2.1.3). There is reason to believe results would have 
turned out differently if cytokine production was evident after overnight stimulation. 
Expansion significantly increased the proportion of mycobacteria-specific CD4+ T cells, but 
due to the aforementioned problems, the proportion of specific cells was much lower than 
would be expected from such an experiment. Still, results are promising for the future, and it 
is hope this can be successfully repeated with other HIV patients in the future, as cells 
otherwise looked healthy after 10 days in culture. Figure 4.13 shows a representative figure 
from another experiment of expanding mycobacteria-specific CD4+ T cells. The proportion of 
specific cells increased ten-fold after expansion. 
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Figure 4.13: Expansion of mycobacteria-specific CD4+ T cells. Effector cytokine production is represented 
by percentage of CD4+ T cells producing TNF (y axis). Left: PBMCs were stimulated overnight using 
heat-killed M.avium, and then stained extracellularly for identification markers and intracellular cytokine 
production. Right: PBMCs were cultured for 10 days in the presence of heat-killed M.avium. On day 10 
they were co-cultured with autologous MDMs that were later stimulated with heat-killed M.avium. After 
co-culturing overnight, cells were stained extracellularly for identification markers and intracellular 
cytokine production. Expansion and analysis of expanded cells were performed by Marit Bakke. 
4.3 Mycobacteria-specific effector cytokine analysis by qPCR 
For the purpose to confirm cytokine production findings from flow-cytometry and to extend 
cytokine analysis from T cells only to all PBMCs in the stimulated wells some of the donor 
samples were stimulated for quantitative PCR (qPCR) and ELISA (4.4) analysis as further 
methods for cytokine analysis. qPCR allows analysis of the intracellular cytokine mRNA 
levels from lysed cells after stimulation and thus the total cytokine production from all cells in 
the well can be quantified. There is, however, a major disadvantage. As all cells in the well 
are lysed, it is not possible to distinguish which cell type produced the mRNA detected. In 
addition to T cells, APCs are present in the lysate and may produce cytokine mRNA. 
 
PBMCs were stimulated overnight (3.2.3), and as no protein transport inhibitor was added, 
produced effector cytokines were secreted into the supernatant. After 16 hours of stimulation, 
the supernatant with the produced cytokines was removed (and used for cytokine detection 
with ELISA as a third method to analyze mycobacteria-specific cytokine production, see 4.4), 
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and the cell suspension was lysed, and mRNA prepared (see section 3.5). Probes used targeted 
three cytokines; IL-1β, TNF and IFN- β. 
 
Results from a healthy donor are presented in figure 4.14. For probes for IFN- β, only heat-
killed M.avium yielded a significant increase in RQ value, but for TNF and IL-1β, there was 
an increase in RQ value for all three mycobacterial antigens above the unstimulated 
calibrator. RQ values are largest for the cytokine IL-1β. Heat-killed M.avium is the 
stimulating mycobacterial agent among the three that yields the best results (i.e. highest RQ 
value) for all three probe pairs. 
 
Figure 4.14: Cytokine production in a healthy donor in response to M.avium PPD, M.tuberculosis PPD as 
well as heat-killed M.avium represented by analysis using quantitative PCR and probes for the three 
proinflammatory cytokines IFN-β, TNF and IL-1β. Cytokine production is indicated by the RQ (relative 
quantification) value and unstimulated control is used as a calibrator, and given the RQ value of 1. As 
endogenous control, the housekeeping gene GAPDH was used. 
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The same procedure was performed on one of the HIV patients to see if cytokine mRNA 
levels deviated from the healthy donor. Unfortunately, it was found that this sample produced 
no cytokines above background during flow cytometric analysis after overnight stimulation 
with mycobacterial antigens (M.avium PPD, M.tuberculosis PPD and heat-killed M.avium), 
see 4.2.1.3. qPCR was performed nevertheless, and it was possible to obtain results using 
probes for the same cytokine mRNA as with the healthy donor; IFN-β, TNF and IL-1β. In 
figure 4.15, results are shown for one of the cytokines, IL-1β. The figure compares the results 
from the healthy control and the HIV patient. It is evident that also the HIV patient produced 
IL-1β mRNA (as RQ values are larger than the calibrator with value 1) but the RQ values are 
far from as high for the HIV patient as it was for the healthy control, ranging only from 20 to 
30 for the HIV patient. 
 
Lysate from additional HIV patients were stored in -80 °C, making the future analysis of 
mycobacteria-specific cytokine production by PBMCs using qPCR possible. 
 
 
Figure 4.15 Cytokine production in a HIV patient compared to a healthy control in response to M.avium 
PPD, M.tuberculosis PPD as well as heat-killed M.avium represented by analysis using quantitative PCR 
and probes for the proinflammatory cytokine IL-1β. Cytokine production is indicated by the RQ (relative 
quantification) value and unstimulated control is used as a calibrator, and given the RQ value of 1. As 
endogenous control, the housekeeping gene GAPDH was used. 
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4.4 ELISA 
The third method used to analyze mycobacteria-specific cytokine production, was ELISA 
(Enzyme-Linked ImmunoSorbent Assay). Supernatants from stimulation as described for 
qPCR sample acquisition (section 4.3) were analyzed for cytokine production. In this 
experiment, TNF was targeted, using the Human TNF-α DuoSet kit provided by R&D 
Systems (refer section 3.6). This method of cytokine production analysis can be said to show 
the same disadvantage as for the qPCR; the lack of ability to distinguish from which cell type 
the cytokines were produced. 
 
ELISA was performed using only one healthy donor. Supernatants from stimulated HIV 
patient samples were stored in 80 °C for future analysis. 
 
Results from the healthy donor is presented in figure 4.16. The results show the presence of 
TNF in the culture supernatants as healthy PBMCs are stimulated overnight using the 
mycobacterial antigens M.avium PPD and heat-killed M.avium. 
 
Figure 4.16: Total mycobacteria-specific production of TNF in supernatants from healthy PBMCs 
stimulated overnight using M.avium PPD and heat-killed M.avium. Amount of TNF is represented by the 
concentration in pg/mL. 
 83 
 
5 Discussion 
 
An estimated number of 1.4 million people will die from tuberculosis every year (1), and the 
problem of co-infection with HIV presents a huge threat in Sub-Saharan areas. BCG, the only 
vaccine available for protection against tuberculosis, has lately been declared ineffective 
against adult, pulmonary tuberculosis (172). 
 
Immune functions against mycobacteria seem to be impaired in HIV patients even after onset 
of antiretroviral therapy (130) and at relatively normal CD4+ T cell counts (173). The reason 
for this increased susceptibility of HIV patients to mycobacterial infections is still unclear and 
thus this project aimed at investigating the immune functions towards M.tuberculosis and 
M.avium in humans infected with HIV and compare to healthy controls. Decreased 
polyfunctionality of CD4 T cells (95)(106)(133)-(139) and skewed T cell differentiation 
(106)(112)(133)(141)-(147) are believed to contribute to the accelerated deterioration of 
immunological functions, and these were central topics for the work. A better understanding 
of the immunological processes involved is also crucial for drug development. 
 
 
CD4 T cells are depleted in HIV patients during infection. At the same time, CD4+ Th1 cells 
are potent producers of IFN-γ, a key cytokine in controlling tuberculosis infection. Their 
absence may therefore in part explain why infection with M.tuberculosis causes such a serious 
threat for HIV patients, and the main focus of this study was directed towards this immune 
cell population. The study of CD4 T cells is commonly done by using technologies of flow 
cytometry, and a main part of this work was the establishment of a multicolor flow cytometric 
assay for simultaneous study of CD4 T cell polyfunctionality and memory differentiation. 
Both healthy controls and HIV patients were enrolled in the study by the donation of 
heparinized blood. 
 
The effect of cryopreservation on T cell effector function was examined by the storage of 
healthy PBMCs at sub-zero temperatures for up to three months and the subsequent analysis 
of viability and cytokine production. Two methods of storage were used; -80 °C and liquid 
nitrogen. Viability was found not to be much affected by cryopreservation, although there 
were signs of a small decrease in viability post stimulation for cells kept in -80 °C. The
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viability seems therefore not to be compromised during cryopreservation, making the analysis 
of surface markers possible even after cryopreservation of PBMCs in regular freeze 
containers holding -80 °C. Cytokine production, however, seems to be best analyzed from 
fresh cells, as frozen cells were not able to completely retain their effector function after 
thawing. Cryopreservation pauses all intracellular activity, and cells seem not to fully recover 
after this, proposing the cryopreservation is not able to pause all activity, or exposes cells to 
irreversible stress. Storage at low temperatures (here: liquid nitrogen) is better for cells, as a 
larger proportion of cells stored in liquid nitrogen are able to produce cytokines than cells 
stored in -80 °C. The results from these experiments led us to the recommendation that 
analysis of CD4+ T cell effector cytokines seems to be best performed from fresh cells. Cells 
stored for up to three months in liquid nitrogen can be used if absolutely necessary and yields 
results that are comparable to fresh cells, but storage in -80 °C is not sufficient for analysis of 
cytokine production. However, both storage methods are recommended for surface marker 
identification, as viability is retained after thawing by careful consideration of freezing and 
thawing protocols. It is not inevitable to think that customizing of protocols may affect the 
effector functions after thawing. For example it could be necessary to distribute protein 
transport inhibitor differently to cells that have been thawed than fresh cells, if frozen cells 
takes longer to recover and cytokine production therefore is slower. There are examples of 
other studies having used cryopreserved PBMCs for intracellular staining of effector 
cytokines as well (98)(174), reporting high viability and effector function. Cryopreservation 
of cells may be necessary if sampled for example from developing countries lacking 
technologies for analysis, and seems to be a widely accepted method for the purpose of 
investigating cytokine production. The advantages of being able to analyze several samples 
simultaneously, and including relevant controls, with the same settings, reduce variability 
between experiments. This may even overweight the disadvantage of reduced total cytokine 
production. 
 
Distribution of protein transport inhibitor to the cells needs to be adjusted to the aim of the 
experiment and the protocol should remain unchanged within different studies. Altering the 
time point of adding protein transport inhibitor alters the resulting cytokine profile of the 
cells. After stimulation and activation of T cells, not all responsive genes are transcribed 
simultaneously (83). Genes transcribed are categorized as immediate, early or late, depending 
on the cell's needs. Cytokines are mainly transcribed in the early phase, but there are also 
individual differences. TNF was found to be the earliest detectable cytokine in supernatant 
Discussion 
___________________________________________________________________________ 
85 
 
from stimulated PBMCs, but it decreased rapidly and to an almost undetectable level when 
IFN-γ peaks (unpublished results from ELISA assays in our research group). When adding the 
protein transport inhibitor after 16 hours and for four hours (as was chosen as the routine 
protocol for this project), there is a risk that the production of some cytokines might be 
missed, if they peak early after stimulation and decrease rapidly. Tests comparing addition of 
inhibitor the next day for just four hours with addition of the inhibitor already one hour post 
stimulation and kept with the cells overnight showed a loss of TNF production when inhibitor 
is added the next day, but an increase in production of IFN-γ. IL-2 remains unchanged for the 
two different methods. When adding the protein transport inhibitor already one hour after 
stimulation and for the whole 16 hours, it would be expected that all cytokines produced in 
that time period accumulates in the cell and are present in the result. However, this seems not 
to be the case, although we found in some samples huge fluorescence values for TNF when 
secretion inhibitor was added early. 
 
The protein transport inhibitor mix contains brefeldin A, a substance that blocks the transport 
of secretory proteins from ER (175), leading to the accumulation of cytokines in the ER 
compartment. The other substance included in the mix, monensin, also have a role in 
inhibiting protein transport. We propose that these compounds exert a toxic damage to the 
cells, interfering with their normal function, and that the mix should be distributed to the cells 
for as short time as possible, while still achieving sufficient amounts of cytokines. The time 
frame for how long cytokine secretion from specific T cells should be inhibited, needs to be 
individually tailored for each study, and keeping to the protocol is an absolute necessity 
throughout a study to minimize variability between experiments and allowing comparison of 
data acquired from different experiments. For our study, we decided to use overnight 
stimulation and then add protein transport inhibitor for another four hours. This resembles 
other studies also leaving the protein transport inhibitor with cells for around five hours (133), 
however, initial stimulation with antigens is often shorter than 16 hours, for example seven 
hours. As our study was based on fresh patient samples requiring PBMC isolation, this would 
be impracticable, and overnight stimulation yielded adequate results. There are, however, also 
examples of incubation with protein transport inhibitor for 16 hours (95)(174). 
 
For choice of cell number per well and fluorochrome amount, compromises must often be 
made. In order to be able to test as many different conditions as possible from a limited 
volume of donor sample, it is desirable to minimize the number of cells used for flow 
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cytometric assays, but still obtain adequate results. Sampling of at least 50 000 cells is 
required for analysis of cytokine production, due to a limited proportion of mycobacteria-
specific T cells that was usually found to be less than 1 % of analyzed cells. For HIV samples, 
this number would preferably be increased to 100 000. Repeated washing steps during 
staining of cells also leads to loss of cells. It was found from the experiments in this study that 
from stimulation of half a million PBMCs in one well of a 96-well plate it was, after 
harvesting, washing and staining procedures, possible to acquire approximately 100 000 
events in the flow cytometer. As there was no significant increase in signal from half a million 
to one million cells per well, half a million cells was found to be an adequate number for 
PBMC stimulation and usually 50 000 cells analyzed in the flow cytometer. As we usually 
received approximately 20 mL of blood, resulting in 15-30 • 106 isolated PBMCs, we could 
thus stimulate 10 samples (5 million cells necessary) plus some controls as well as freeze 
down two tubes (4-7.5 • 106 cells each) with donor PBMCs for repeat analysis. 
 
To determine the concentration of fluorochromes to add for each sample, manufacturer's 
provided guidelines is often a good starting point. For example BioLegend adjust their 
concentrations to a 5 μl «test size», and «The test size products are pre-titrated for optimal 
staining of 1 million cells in 100 µl volume»(176). Ideally, amounts should be tested 
(«antibody titer») for each individual study. It was desirable to see how much this 
recommended amount could be lowered without the subsequent loss of signal, and different 
concentrations of dye for intracellular cytokine staining was tested. It became apparent that 
volume should not be decreased too much, as that would lead to a false low signal, as minimal 
amounts of fluorescent dye fail to stain all cells. A concentration was chosen that produced 
sufficient results for out purpose, however, this is below that recommended by the 
manufacturer, and needs perhaps be increased. However, this needs to be validated using 
proper negative controls and deciding on a proper signal-to-noise ratio. 
 
Storage of flow tubes was found possible for at least up to five day without any obvious 
change in fluorescence signal. Manufacturers claim even the unstable tandem dyes are stable 
for up to three days. Despite this, samples were always analyzed on the same day as the 
intracellular staining procedure. 
 
The analysis of T cell effector functions and memory differentiation in healthy controls versus 
HIV patients took use of the optimized methods for isolation of PBMCs, stimulation and 
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extracellular and intracellular staining of surface markers and effector cytokines. Variability 
in anti-mycobacterial T cell response among healthy donors was found to be quite large and 
greatly influenced the results. This also makes generalization of effector cytokine response 
among healthy individuals complicated. This donor variation may originate from previous 
exposure to mycobacterial antigens, via vaccines or bacteria in the environment (177). The 
BCG vaccine was a part of the Norwegian Childhood Vaccine Program up until 2009, when it 
was taken off the list due to a low prevalence of disease and the believed inefficiency of the 
vaccine (178). The vaccine should provide long-term immunization by stimulating immune 
cells to differentiate into memory cells that will recognize mycobacterial antigens upon 
second encounter. We were able to retrieve one blood sample from a non-BCG vaccinated 
healthy donor, originating from a country where BCG-vaccination is not standard during 
childhood. It was found that this BCG naïve donor had a small, but existing, population of 
CD4+ T cells which produced effector cytokines in response to stimulation with 
mycobacterial antigen. The percentage of specific CD4+ T cells was below the mean for the 
rest of the healthy donors, indicating that the BCG vaccine does play a role in evoking the 
immune system and establishing a pool of memory cells. The degree of polyfunctionality for 
the non-vaccinated donor was found to be a bit below the mean for the rest of the healthy 
donors, and combined with the low overall frequency of specific cells, this means very few 
cells produced all three cytokines. Polyfunctionality of CD4+ T cell responses may be a 
prerequisite for protective immunity against tuberculosis (92)-(97). The variability between 
the rest of the healthy donors is not easy explainable, but probably points to a general feature 
of the population. This could perhaps be due to environmental exposure or individual 
differences in immune response. 
 
A central step during tuberculosis infection is the activation of T cells recognizing 
mycobacterial antigens, resulting in production of CD4+ Th1 cytokines IFN-γ and TNF that 
are of great importance in elimination of intracellular pathogens. Mice defective in IFN-γ 
succumb rapidly to infection with MTB (81)(80). Genetic susceptibility studies in humans 
have further revealed that defects in for example IFN-γ signaling (179) increase the risk for 
disseminated nontuberculous mycobacteria (NTM) diseases (described in (180)). It also seems 
like there is some kind of kinetics involved in cytokine production from T cells, where TNF is 
secreted early after stimulation and IFN-γ a bit later. Highest amount of IFN-γ are detected 
when protein transport inhibitor is added after overnight stimulation and for another four 
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hours. Response towards M.avium resembles that of M.tuberculosis, due to great similarities 
between the two species, they share 75 % of the same proteins (181). 
 
Response in our study towards mycobacterial antigens were characterized by a considerable 
production of IFN-γ after overnight stimulation. This trend was seen for both healthy donors 
and one of the HIV patients, making IFN-γ the predominant cytokine produced in single 
producers for most of the donors. No considerable difference in production of IFN-γ was 
found in the response towards M.tuberculosis and M.avium, both healthy individuals and HIV 
patients responded to antigens from both agents. This trend can be further investigated as 
more participants are enrolled in the study. Infection with M.avium is a complication among 
patients with severe AIDS disease, and it is possible that response towards M.avium differs 
from that towards M.tuberculosis, even though the bacteria share great similarities. 
 
TNF is a proinflammatory cytokine produced by activated macrophages and T cells. The 
cytokine plays a role for granuloma development and containment of infection with 
M.tuberculosis and M.avium (182)(86)(183)(184), although the importance of TNF in mouse 
M.avium infections is not fully clarified (185)(186). Recently our group found surprisingly 
low levels low levels of TNF in M.avium -infected mouse tissue (Haug et al. 2013 submitted). 
For our study, it was found that TNF levels were usually present to a less degree than IFN-γ, 
but a significant proportion of the single producers secreted TNF. For one of the healthy 
donors and one HIV patient, TNF was the predominant cytokine produced in response to heat-
killed M.avium. TNF seems to peak early after stimulation, and the chosen window for 
cytokine secretion may not be optimal for accumulation of TNF in mycobacteria-specific 
CD4+ T cells. For the one non-BCG vaccinated healthy donor, the production of TNF in 
single producers seemed to be somewhat higher compared to the production of IFN-γ. 
Significant amounts of TNF were also found in healthy controls during ELISA and PCR 
analysis. For PCR, the response was largest towards heat-killed M.avium, however, the 
response was largest towards M.avium PPD in ELISA. These methods are not cell specific, 
and may, in addition to production by T cells, also reflect the ability of for example 
macrophages to produce TNF in response to stimulation. TNF has received great interest in 
HIV patients, but its role and expression are debated. TNF regulation seems to be impaired in 
HIV patients (described in (187)). 
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As already mentioned, IFN-γ produced by T cells are important for macrophage activation, 
and TNF is important for granuloma maintenance in tuberculosis infection. There has recently 
also been focus on cells that are also capable of IL-2 production, as IL-2 is important for T 
cell proliferation and self-renewal. T cells simultaneously producing several of these 
cytokines are called polyfunctional T cells. Polyfunctionality, or the quality, of CD4+ T cells 
receives increased interest, and the simultaneous production of IFN-γ, TNF and IL-2 has been 
shown to correlate with long-term protective immunity against M.tuberculosis (97), as well as 
vaccine-induced protection against L.major (188). However, it was recently suggested that 
this polyfunctionality alone is not sufficient for long-term immunity (189). 
 
As HIV patients are, even at relatively normal T cell counts, more susceptible to 
mycobacterial infections than healthy individuals, there might be differences in the 
polyfunctionality. Although we could in this study test only T cell responses towards 
mycobacterial antigens from a very low number of patients, cytokine production for HIV 
patients seems to be characterized by a low degree of polyfunctionality. The low number of 
study participants, and problems with low CD4 T cell count and/or low proportions of 
mycobacteria-specific T cells makes it difficult to draw definite conclusions, but from the 
preliminary results obtained, there seems to be a marked decrease in polyfunctionality of 
mycobacteria-specific CD4+ T cell responses i HIV patients. Most samples showed almost a 
total monofunctionality towards the different antigens (ranging from 70 to 92 % single 
producers and 0 to 20 % triple producers for the three different mycobacterial antigens ). This 
in contrast to the healthy individuals, where polyfunctionality was always present to some 
degree (triple producers ranging from 4 to 14 % for the three different mycobacterial 
antigens). These results correspond to other studies (138)(133), where polyfunctionality was 
also found to be impaired during HIV infection. 
 
A generally low total mycobacteria-specific CD4+ T cell response (in % of CD4+ T cells) 
was found among some HIV positive donors compared to the mean of the healthy donors. 
This correlates to other recent findings (133). However, as all recruited HIV patients followed 
therapy at the time of blood sampling, results are contrary to studies where anti-mycobacterial 
CD4 T cell frequencies were found to be restored by HAART (134)(135). Interestingly, the 
highest proportion of mycobacteria-specific T cells (in % of CD4+ T cells) was found to 
belong to the HIV patient with the lowest number of CD4 T cells. Similar results have been 
reported by others as well (137). 
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In summary, our preliminary results indicate that HIV patients might have an impaired 
polyfunctionality of their mycobacteria-specific T cell population. As a consequence, this 
correlation may impact their increased susceptibility towards tuberculosis, even though their 
CD4 T cell population is restored by treatment with HAART. 
 
CD4+ T cells are depleted in HIV patients, but the population is restored during treatment 
with HAART. This may impact the status of the CD4+ memory T cell population, as memory 
T cells may be depleted and replaced with naïve T cells. As a consequence, HIV patients may 
experience a difference in their memory T cell composition as compared to healthy 
individuals. The memory population is very heterogeneous and hard to characterize, as a 
variety of surface markers are up- and downregulated during memory differentiation. A set of 
markers were chosen after literature studies, and their expression was studied in HIV patients 
and healthy controls. The chosen markers were, as follows: CD27, CD28, CD45RO, CD57, 
HLA-DR, PD-1 and CCR7. Identification markers CD3, CD4 and CD8, as well as cytokine 
production (IFN-γ, TNF and IL-2) were also included for the study of memory markers. 
Unfortunately, CD28 often yielded unreliable results, and were excluded from further 
analysis. One analysis was even performed on the CD8+ T cell memory population, and it is 
possible to look further into this population at a later stage. 
 
In this study, memory differentiation among healthy donors was shown to shift between the 
whole CD4 population and the specific cells. CCR7 showed a decrease in expression in the 
specific cells, indicating that these cells are of a more differentiated effector memory 
phenotype, these cells are described as TEM (58). Cytokine production has been found in other 
studies to increase with the loss of CCR7 expression (119)(102), which is in agreement with 
the results mentioned. CD27 should be expressed on all naïve T cells and most memory cells, 
but the expression has been described to be lost during memory differentiation (107). In our 
experiments, for the healthy donors, CD27 expression clearly decreased in activated and 
specific cells compared to naïve CD4 T cells. This means the specific cells have undergone 
further differentiation. CD27- cells have been associated with high effector functions in CD8 
T cells (59), a phenomenon also described by other studies (119). 
 
The splicing of CD45RA to form CD45RO upon antigen encountering is a well-known 
feature characterizing the majority of memory T cell subsets (103)(104). Among healthy 
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donors, all mycobacteria-specific CD4+ T cells were found to express CD45RO, whereas 
only 40 % of the total CD4+ T cells expressed CD45RO with the rest of the cells probably 
being naïve cells. Expression of CD45RO may, however, be lost at late stages of CD4 T cell 
differentiation. Expression of CD45RA is then regained, forming the so-called TEMRA 
subpopulation of TEM (59)(60). 
 
Expression of PD-1 was in our characterization of healthy donors found to be higher in 
specific cells than in the CD4 population as a whole. This is consistent with findings of PD-1 
being present on effector memory cells rather than central memory cells and naïve T cells 
(113). Expression of HLA-DR was found almost absent from the CD4 T cell population as a 
whole, but is, consistent with other findings (114) (115) present on a larger proportion of the 
activated or specific CD4 T cells in healthy donors. 
 
While most naïve T cells are CD27+CCR7+, expression of CD27 as well as CCR7 is 
gradually lost as CD4 T cells mature from naïve into cytokine-producing memory cells. For 
the total CD4+ T cell population in healthy donors, we found the majority of cells to be of a 
CD27+CCR7+ phenotype, although a significant proportion was CD27+CCR7-, and some 
were CD27-CCR7-. Looking only at the mycobacteria-specific effector CD4+ T cells we 
found CD27 and CCR7 differentially expressed with CD27-CCR7- as the predominant. This 
is consistent with the description of an effector memory T cell phenotype where CD27 
expression may be both present and absent, and  the CD27- effector memory cell population 
are associated with a great effector function and advanced differentiation (107)(119)(58). 
Some of the mycobacteria-specific effector CD4+ T cells were CD27+CCR7-, and a few 
CD27+CCR7+. 
 
We did not fint cells of the CD27-CCR7+ phenotype for any of the two CD4+ T cell 
populations, indicating CCR7 expression is lost before CD27 expression. Some cells, both in 
the total as well as mycobacteria-specific T cell population of healthy donors were found to be 
CD27+CCR7-.  
 
When comparing the expression of the memory markers on the total CD4+ T cell population 
in healthy individuals and HIV patients, we did not see obvious variations for most of the 
markers. The marked decrease of CD27+ T cells, as reported (147), was not seen, and the 
expression of CD45RO and CCR7 were also similar for the two groups. HLA-DR and PD-1, 
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however, seem to be more frequently expressed on CD4+ T cells of HIV patients. It has been 
observed by others (190) that expression and replication of HIV is higher in HLA-DR positive 
than HLA-DR negative T cells, and that expression of HLA-DR correlates with higher 
expression of HIV.  This could mean these cells are infected with HIV. 
 
The PD-1 pathway induces replicative senescence and inhibits cytokine production from T 
cells. Blocking of this pathway restores these characteristics in CD8+ T cells (145). The 
reduced capacity to produce cytokines is not necessarily due to the expression of PD-1 itself 
(146). It was reported by other studies that HIV-specific CD8+T cells show increased 
expression of PD-1, and this may be independent of their maturational status (146). The 
expression of PD-1 on CD4 T+ cells is also correlated with viral load and negatively 
correlates with CD4+ T cell count (112), which may explain the increase in PD-1 expression 
that we found in our study on total CD4+ T cells of HIV patients. 
 
Studies have shown that untreated HIV patients have a higher proportion of CD4+CD57+ 
than seronegative individuals (144), indicating that many cells are unable to divide, and that 
therapy did not normalize these conditions. The same study indicated that CD57 expression 
was predominantly found in the CCR7- T cell population and mainly among the CD4 T cells 
producing IFN-γ alone (144). Our findings show that CD57 is more expressed in healthy 
donors than in HIV patients, and thus seem not in accordance with Palmer and colleagues. It 
can generally be said that expression is low in both groups. It should be noted that CD57 was 
not identified for all study participants, as the fluorescence channel was mainly used for 
identification of CCR7. Additional samples are required to draw conclusions, but this could 
mean that our patient cohort show a normal expression of CD57, and that the CD4+ T cells 
are able to divide as normal. 
 
Comparison of total and mycobacteria-specific CD4+ T cells from HIV patients regarding 
CD4+ T cell memory status is difficult due to the small number of analyzed donors for 
specific T cells from patients so far. Analysis of more donor samples are needed before 
conclusions can be drawn. In addition, the fairly low number of specific cells made the 
analysis complicated, and results seem to differ a whole lot from the healthy controls. For 
HIV it has been said that increased memory differentiation among the CD8+ T cell population 
is associated with decreased polyfunctionality (143). Others again claim that HIV-infection 
does not alter the T cell memory phenotype (133). 
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As for the healthy donors, we found for the HIV patients, total CD4 T cells to be mainly of a 
CD27+CCDR7+ phenotype. Our preliminary findings seem to point towards some differences 
between healthy and HIV patients when taking the specific CD4 T cell population into 
consideration. Results indicate that the majority of the specific T cells are CD27+CCR7+, the 
rest being almost equally distributed between CD27+CCR7-, CD27-CCR7+ and CD27-
CCR7-. This means a lot of the specific cells show a phenotype indicating an early 
differentiated stage compared to the healthy controls. As earlier mentioned, loss of CCR7 
expression is associated with an increase in cytokine production (119)(102). Among the HIV 
patients, around 40 % of the specific cells seem to experience the CCR7- phenotype, the 
percentage is more than 90 % in the healthy individuals. This may indicate that the memory 
status of mycobacteria-specific CD4+ T cells in HIV patients is different from healthy 
controls with a higher proportion of CCR7+ cells. This might contribute to the lower 
proportion of cytokine-producing mycobacteria-specific cells in (some) HIV patients. In 
addition, this finding supports the view of specific memory CD4 T cells of HIV patients being 
of an early differentiated stage, as represented by the intact expression of CCR7 in the 
majority of the cells. As effector memory cells (predominant in the healthy individuals) lack 
the CCR7 marker, most memory T cells in our HIV patient cohort seem to be of another 
memory T cell population than TEM, which contradicts earlier reports (106). From these 
results, specific memory CD4 T cells from HIV patients seem to be of an central memory 
phenotype, TCM. This subset is characterized by little cytokine production, but is able to 
differentiate further to effector cells (58). 
 
Detection of intracellular cytokine mRNA expression using quantitative real-time PCR yields 
results showing that PBMCs stimulated overnight with mycobacterial antigens does produce 
proinflammatory cytokines. This method of analyzing cytokine production is not cell-specific. 
That means the whole PBMC population is analyzed for cytokine production, not just the T 
cells. PBMCs are a large group of cells that in addition to T cells also include for example B 
cells, DCs and monocytes/macrophages. This means real-time qPCR is not the best method 
for a project like this, where the T cells are in focus. Still, it provides an image of the overall 
PBMC status, and thus gives and idea of the total cytokine production. The different 
cytokines are also induced by different signaling pathways. IFN-β may be induced by TLR4 
and the subsequent activation of transcription factor interferon regulatory factor (IRF) 3 and 7 
(191). TNF is an inflammatory cytokine that mainly signals via TLRs and transcription factor 
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NF-κB (192), whereas IL-1β is secreted in response to activation of inflammasomes 
(reviewed in (99)). For all three sets of probes (IFN-β, IL-1β and TNF) the negative, 
unstimulated control shows little response, whereas heat-killed M.avium shows the greatest 
response towards all three mycobacterial antigens. 
 
In the qPCR experiments, an increase in signal from stimulation with heat-killed M.avium 
compared to purified protein derivatives (PPD) from M.avium and M.tuberculosis was seen. 
This can perhaps be explained by the fact that PPD consists only of isolated proteins from 
bacteria. Heat-killed bacteria are complete organisms, just inactivated, meaning they perhaps 
are better at mounting an immune response as they better resemble the real situation of 
infection. However, the differences in cytokine mRNA production from total PBMCs between 
PPD and heat-killed mycobacteria seems not to affect T cell activation, as no significant 
difference was seen between the two stimulating agents in flow cytometric analysis. 
 
ELISA targeting TNF was used as a third method for analysis of total mycobacteria-specific 
cytokine production from PBMCs. This assay was performed using only one healthy donor. 
However, supernatants from overnight stimulated PBMCs using mycobacterial antigens were 
stored in freeze containers for future analysis. ELISA results also show a production of 
proinflammatory cytokines from PBMCs stimulated with mycobacterial antigens overnight. 
This method shares a disadvantage with PCR, it is not possible to know from which cells the 
cytokines originated. 
 
One of the most important limitations of this study was the relatively small number of HIV 
patients. Due to a late approval of the project by the regional ethics committee, the process 
delayed, and before the end of the study, it was possible to recruit only seven HIV patients. 
The pool of HIV positive patients in Trondheim approaches 120, and patients are not often in 
for controls. To increase the number of samples, it is possible establish a cooperation between 
research groups, in Norway and even across national borders. 
 
Also, only 2 % of T cells are found in the blood stream (54). Although both major types of 
memory T cells are supposedly present in the blood (reviewed in (59)), effector memory T 
cells express surface markers making them home to infected tissues. Responses in T cells of 
the lung, where mycobacteria enter the body, may not resemble the responses found in 
peripheral blood. 
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6 Conclusion and future perspectives 
 
In this study, methods for investigation of anti-mycobacterial CD4+ T cell effector functions 
and memory T cell composition in HIV infected individuals were established and applied. 
Individuals with underlying HIV infection are more susceptible to mycobacterial infections 
than healthy individuals, even after the onset of therapy. We hypothesized that this is due to 
impaired CD4+ T cell quality and skewed CD4+ T cell memory differentiation. To investigate 
these matters, we recruited HIV patients from the indoor clinic at St. Olavs Hospital, as well 
as healthy controls from the institute staff members. Peripheral blood mononuclear cells 
(PBMCs) were isolated and stimulated using mycobacterial antigens (PPD from 
M.tuberculosis and M.avium, as well as heat-killed M.avium), and the mycobacteria-specific 
CD4+ T cell cytokine response and memory differentiation were studied. Flow cytometry was 
the main method used, but cytokine production was confirmed using qPCR and ELISA. 
 
Before characterization of mycobacteria-specific CD4+ T cell immune responses in HIV 
patients, we established a protocol to ensure best possible conditions for simultaneous 
analysis of CD4+ T cell cytokine production and memory differentiation. The effect of 
cryopreservation on cytokine production was assessed, and it was found that cryopreservation 
for PBMCs for up to three months in liquid nitrogen yields results that are comparable to 
those from fresh cells. However, total percentage of mycobacteria-specific CD4+ T cells 
decreased as cells were stored at sub-zero temperatures, and we concluded that use of fresh 
cells should be considered. Cryopreservation may be useful if necessary technologies are 
limited, or to reduce variability between experiments by analyzing a set of samples 
simultaneously, including relevant controls. 
 
We established a multicolor flow cytometric assay where we simultaneously could analyze 
CD4 T cell identification markers (CD3, CD4 and CD8), intracellular cytokine production 
(IFN-γ, TNF and IL-2) and memory markers (CD27, CD28, CD45RO, CD57, HLA-DR, PD-
1 and CCR7). 11 fluorochromes were analyzed at the same time. For each donor sample, 10 
wells were stimulated (plus controls), half the set was stained for the analysis of CD4+ T cell 
cytokine production, while the other half was stained for the analysis of CD4+ T cell 
differentiation status. Relevant controls were always included to be able to distinguish
Conclusion and future perspectives 
___________________________________________________________________________ 
96 
 
between negative and positive populations during flow cytometric assay, and for the 
evaluation of signal-to-noise ratio. Fluorochromes were carefully chosen and brighter colors 
were designated the least abundant populations (cytokines, but also memory markers). 
 
Response from mycobacteria-specific CD4+ T cells to overnight stimulation with antigens 
from M.tuberculosis and M.avium was detected in both healthy donors and HIV patients. This 
response manifested by the identification of effector cytokines IFN-γ, TNF and IL-2 during 
flow cytometric assays. The frequency of total CD4+ T cell responses to overnight 
stimulation with mycobacterial antigens was low, usually below 1 %. Polyfunctionality of 
CD4+ T cells is believed to be central in mounting a potent immune response towards 
mycobacteria, and it has been proposed that the decrease in CD4+ T cell polyfunctionality 
among HIV patients may contribute to their impaired immune response. We were able to 
analyze the mycobacteria-specific CD4+T cell cytokine production from two HIV patients 
only, but when comparing their results with the healthy individuals, our preliminary findings 
point to a lower polyfunctionality among the mycobacteria-specific CD4+ T cell population. 
This may be important in explaining the increased susceptibility of HIV patients to 
mycobacterial infections, and may confirm that the increased risk is not restored by 
antiretroviral therapy. These preliminary results should be verified by enrolling more HIV 
patients to the study, as great donor variability was discovered among the healthy controls, 
which may also be the case among HIV patients. 
 
In addition to decreased polyfunctionality, skewed CD4+ T cell memory composition in HIV 
patients may influence the response towards mycobacteria. When considering the total CD4+ 
T cell population and comparing healthy controls to HIV patients, we did not find large 
differences for most of the memory markers. However, HLA-DR and PD-1 seem to be more 
frequently expressed in HIV patients than in healthy individuals. Interestingly, the 
mycobacteria-specific CD4+ T cells of HIV patients seem to be of an earlier differentiated 
phenotype, as indicated by a large proportion of CD27+CCR7+ cells. Among the healthy 
individuals, few cells are CD27+CCR7+, the predominant phenotype is CD27-CCR7-, 
indicating cells are late differentiated. Cytokine production is believed to peak as CCR7 
expression is lost, in the effector memory cell population. Long-term immunity potential, 
however, may be best preserved as CCR7 expression is intact. These preliminary results 
suggest there are significant differences in CD4+ T cell memory population composition 
between healthy individuals and HIV patients. This needs to be further investigated, as it was 
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possible to analyze the mycobacteria-specific CD4+ T cell memory phenotype from very few 
HIV patients. 
 
In summary, our preliminary findings point to central differences between healthy controls 
and HIV patients in mycobacteria-specific CD4+ T cell effector cytokine production and 
polyfunctionality, as well as CD4+ T cell memory phenotype. Results from this pilot study 
should be further validated with more HIV patients. 
 
The results from our study might after completion contribute to a better understanding of 
abnormalities in the CD4+ T cell responses (polyfunctionality and memory subset 
composition) of HIV patients. Increased knowledge of the T cell subsets necessary for 
successful anti-mycobacterial immunity is important to develop new and more effective 
vaccine strategies. Vaccines against tuberculosis are urgently needed, as tuberculosis is a 
global problem, and multidrug-resistant strains are on the rise.  
 
The results already obtained can be used as indications for further research. As additional HIV 
patients are recruited to the study, it would be possible to group the patients according to their 
disease progression. Healthy controls may be compared to HIV seropositive individuals 
before onset of therapy, and patients already receiving therapy. Their responses towards 
stimulation with mycobacterial antigens may be compared to investigate how susceptibility to 
tuberculosis changes during disease progression. This may also be correlated to CD4 T cell 
count and even viral load. If possible, it would be interesting to do follow-up analysis on the 
same patient, preferably before and after onset of antiretroviral therapy. In Norway, however, 
therapy is initiated quite soon after HIV is diagnosed and without waiting for CD4+ T cells to 
decrease under a certain limit, which means HIV patients before onset of therapy are hard to 
find. To increase the patient cohort, collaboration with other national and international 
research groups is an option. This is a possible option as we here showed that CD4+ T cell 
functions can be analyzed from cryopreserved samples, thus allowing to ship isolated PBMCs 
on dry ice. Long-term nonprogressors (or elite controllers) could also be enrolled in the study. 
These are HIV positive individuals who control the disease without treatment with 
antiretroviral therapy. 
 
A promising finding was the ability to generate an expanded population of mycobacteria-
specific T cells from the isolated PBMCs from one of the HIV patients. T cells stimulated 
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with mycobacterial antigens were cultured for approximately 10 days, and autologous MDMs 
were generated simultaneously. In vitro-generated macrophages that can be co-cultured with 
antigen-specific CD4+ T cells opens for a wide variety of manipulations. Macrophages may 
be modified, using for example siRNA knock-down of proteins, and mycobacteria can also be 
modified. It should also be noted that shortly, there will be facilities available for handling 
live M.tuberculosis at the institute, which also increases the possibilities for more realistic 
analysis of immune responses during in vitro co-infection with HIV and tuberculosis. 
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Appendix I: Isolation of PBMCs 
 
Material: Heparinized venous blood from healthy donor or HIV positive patient. 
 
All solutions should be room temperature. 
 
In a 50 mL tube, add around 15 mL blood. Add PBS up to 30 mL. 
 
In another 50 mL tube, add 15,0 mL of Lymphoprep. Use a 25 mL pipette and gently add the 
blood/PBS mix to the Lymphoprep so that it forms a layer on top of the blank solution. 
Spin tubes at 1800 rpm for 20 minutes at room temperature (brake 7^3). 
 
The white blood cells now form a ring between the Lymphoprep and the serum. Remove this 
ring of WBCs with a 10 mL pipette and add to a new 50 mL tube. Remove about 10 mL of 
fluid, be careful not to include too much Lymphoprep, as it is toxic to the cells. Spin at 2000 
rpm for 10 minutes at room temperature. 
 
Washing step 1: Gently remove the supernatant and discard it. Leave some fluid in the tube to 
avoid losing cells. Resuspend the cells in the remaining liquid and add HANKS 2% FCS up to 
25 mL. Spin at 800 rpm for 8 minutes at room temperature. 
 
Washing step 2: Gently remove the supernatant and discard it. Leave some fluid in the tube to 
avoid losing cells. Resuspend the cells in the remaining liquid and add HANKS 2% FCS up to 
25 mL. Spin at 1400 rpm for 6 minutes at room temperature. 
 
Gently remove the supernatant and discard it. Leave some fluid in the tube to avoid losing 
cells. Resuspend the cells in the remaining liquid and add RPMI medium (+Glu+HEPES) 
10% A+ up to 5 mL. 
Count the cells using Countess: Mix 10 uL Trypan blue and 10 uL sample, and add to a count 
slide. Follow instructions on the machine. 
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Appendix 2: Protocols for HIV study 
Biobanking of PBMCs 
Freezing cells 
Prepare freezing medium (80% FCS 20% DMSO) and add 0,5 mL to cryo tubes (size 1,2 
mL). 
Transfer PBMCs to a 15 mL tube. Dilute to 5 mL using PBS 2% FCS. Spin at 1400 rpm for 6 
minutes. Discard supernatant. Use a 1000 uL pipette to remove as much of the supernatant as 
possible, but be sure not to throw away any cells. 
Carefully resuspend the cells in pure FCS and transfer 0,5 mL to each cryo tube. 
Cryo tubes are then placed in Mr Frosty and Mr Frosty is placed in  -80 °C. Cells going to 
liquid nitrogen are removed after 24-72 hours. 
Thawing PBMCs 
Cells should be thawed as quickly as possible after removal from freezer/nitrogen. 
Prepare medium (RPMI 10% FCS) and heat it to in 37 °C. 
Loosen the cap of the tubes a bit and thaw by placing in water bath (37 °C) or under hot 
running water. As soon as they are completely thawed, move cells to 5 mLwarm medium and 
wash the cryo tubes once. 
Spin cells at 1300 rpm for 5 minutes. Discard the supernatant and resuspend carefully in 
remaining liquid by flicking the tubes. 
Add medium (RPMI+Glu+HEPES+10% A+) to 1 mL and count the cells. 
Dilute the cells and proceed with stimulation 
Stimulation of mycobacteria-specific T cells 
Dilute the cells (thawed or fresh) to a working concentration of 2,5 x 106 cells/mL in T cell 
medium (RPMI +Glu+HEPES+10% A+) 
Add costimulatory signal (anti-CD28 and anti-CD49d). 
Pipette 0,5 x 106 cells/mL (equals 200 uL) in a 96 well round-bottom plate. 
Stimulate the cells: 
 Unstimulated 
 M.avium PPD 10 ug/mL 
 M.tuberculosis PPD 10 ug/mL 
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 Heat-killed M.avium (MOI 1:1 = 0,5 x 106 bacterias per well, calculate from 
OD measured) 
 1:10 diluted eBioscience 500x cell stimulation cocktail, 4 uL 
Incubate overnight (16 h) at 37 °C. 
Last four hours: Add 1:10 diluted eBioscience 500x protein transport inhibitor cocktail, 4 uL. 
Extracellular staining 
Transfer cells to flow tubes containing 500 uL flow wash buffer (PBS 2% FCS), and wash 
tubes once (1500 rpm, 6 minutes). Discard supernatant. 
Pool the surface antibodies and add them to the cells (1 uL of each antibody). 
Vortex gently. Incubate 15 minutes, dark and on ice. 
Live/dead stain (eBioscience fixable viability dye eFluor 780) 
Add 0,5 mL PBS to each well. Wash cells at 1500 rpm for 6 minutes and discard the 
supernatant. Repeat this process once. 
Add 0,5 mL PBS to each well, and then add 0,5 uL live/dead stain. Vortex gently, and 
incubate for 30 minutes, dark and on ice. 
Add 0,5 mL wash buffer, and spin at 1500 rpm for 6 minutes. 
 
Discard supernatant. Resuspend cells in 0,5 mL freshly prepared PBS 2% PFA, and incubate 
20 minutes in room temperature and in the dark. 
Spin cells at 1500 rpm for 6 minutes, and discard supernatant. Resuspend in 0,5 mL wash 
buffer and spin at 1500 rpm for 6 minutes. 
Discard supernatant, add 0,5 mL wash buffer, and proceed with intracellular staining or leave 
at 4 °C and dark overnight. 
Intracellular staining 
Spin cells at 1500 rpm for 6 minutes and discard supernatant. 
Resuspend cells in 0,5 mL permeabilization buffer (PBS 1% FCS 0,5% saponin). Incubate for 
5 minutes in room temperature before spinning at 1500 rpm for 6 minutes. Discard 
supernatant. Repeat this procedure once. 
Pool the intracellular antibodies and add them to the cells (1 uL of each antibody). 
Vortex gently. Incubate 30 minutes, dark and in room temperature. 
Add 0,5 mL of the regular wash buffer and wash at 1500 rpm for 6 minutes. Discard 
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supernatant. Repeat this procedure once. 
Resuspend cells in 2-3 drops wash buffer before running flow cytometry. 
Lysate for PCR and supernatant for ELISA 
Stimulation is performed the same way as for flow cytometry, except they are seeded in 48 
well plates (0,5 mL – 1,25 x 106 cells). 
After 16 hours, spin down the whole plate at 1400 rpm for 6 minutes. 
Supernatant 
Remove the supernatant, be careful not to touch the cell pellet with the pipette tip (remove 
around 450 uL). Put supernatant in a new 48 well plate and freeze in -80 °C. This supernatant 
can be analyzed using ELISA. 
Cells 
Add 350 uL lysis buffer to each well (lysis buffer = RCL with mercapoethanol). This should 
be done quickly after removal of supernatant, as cells may dry out. Pipette up and down a 
couple of times. 
Let work for 2-3 minutes. 
Resuspend thoroughly 6-7 times and remove all of the liquid to a new 48 well plate. Freeze in 
-80 °C. Thaw for RNA isolation and eventually PCR. 
T-cells and macrophages for expansion experiment 
Making  an expanded population of mycobacteria-specific T-cells 
Day zero: Dilute PBMCs to a working concentration of 3,5  x 106 cells/mL in RPMI 10% A+. 
Seed cells in flat bottom 24 well plates, 1 mL per well. Stimulate T-cells using heat-killed 
M.avium, MOI 5:1. Incubate in 37 °C . 
At day two/three: Add IL-2 to the T cells. Units: 20 
Split cells and give them fresh medium if they reach confluence over 80%. 
Making autologous monocyte-derived macrophages (MDM) 
Day zero: Dilute PBMCs to a working concentration of 2 x 106 cells/mL in RPMI 10% A+. 
Seed cells in flat bottom 96 well plates, 100 uL per well. Incubate cells in 37 °C  for 1 hour to 
have the monocytes adhere to the plate. 
Remove medium and wash cells three times using warm HANKS. Avoid cells drying out. Add 
RPMI 30% A+ to the cells and incubate in 37 °C  for 6-8 days. 
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Keep an eye on the cells and add more medium if nutrients become scarce. 
Adding T-cells to macrophages 
Day 6-8: Wash T-cells (HANKS 2% FCS) and count them using Countess. 
Stimulate macrophages using the preferred agents. 
Add T cells to macrophages in the flat bottom 96 well plate. Use 0,5 x 106 cells/well. Co-
culture for 16 hours, add protein secretion inhibitor, and proceed with extracellular staining, 
intracellular staining, and flow cytometry. 
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Appendix 3: Staining panel 
 
Staining for cytokine effector functions 
EPITOPE FLUOROCHROME 
CD3 BV785 
CD4 BV711 
CD8 Alexa 700 
Live/dead eFluor780 
IFN-γ PE 
TNF BV421 
IL-2 APC 
CD45RO FITC 
CD28 PE/Cy7 
CD27 BV510 
PD-1 BV605 
 
Staining for identification of cell surface markers 
EPITOPE FLUOROCHROME 
CD3 BV785 
CD4 BV711 
CD8 Alexa 700 
Live/dead eFluor780 
IFN-γ / TNF / Il-2 PE 
CD45RO FITC 
CD28 PE/Cy7 
CD27 BV510 
PD-1 BV605 
HLA-DR APC 
CCR7 or CD57 BV421 or eFluor450 
 
